🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cologne
Clinical trial register · Germany

Clinical Trials in Cologne, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca48 Novartis Pharmaceuticals29 University of Cologne25 Janssen Research & Development, LLC21 Bristol-Myers Squibb21
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Cologne

612 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Berlin, Hanover, Münster, Cologne, Homburg, Leipzig, Kiel, Essen
2027-11-23
Not yet open
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562Systemic Sclerosis
DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Berlin, Cologne, Erlangen, Leipzig, München, Tübingen, Würzburg
2027-02-03
Not yet open
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
NCT07084831Schizophrenia; Psychosis, Cognitive Impairment
European Group for Research In Schizophrenia
Phase 3
171
Augsburg, Cologne, Mannheim, München
2027-01-01
Not yet open
Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care
NCT07699640Testicular Cancer, Testicular Germ Cell Tumor
Heinrich-Heine University, Duesseldorf
Not applicable
171
Ulm, Würzburg, Hamburg, Marburg, Cologne, Düsseldorf, Wuppertal, Dresden
2027-01
Not yet open
Dalbavancin Therapy for Infective Endocarditis
NCT07699211Endocarditis Infective, Endocarditis, Bacterial
DrugDalbavancin administration
Stefan Hagel
Phase 3
184
Freiburg im Breisgau, Regensburg, Hamburg, Cologne, Leipzig, Berlin, Erfurt, Jena
2026-12
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide
AbbVie
Phase 3
520
Freiburg im Breisgau, Karlsruhe, Tübingen, Ulm, Würzburg, Hanover, Bonn, Cologne
2026-11-30
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
DrugNerandomilast
Boehringer Ingelheim
Phase 3
270
Bad Bramstedt, Berlin, Cologne, Erlangen, Freiburg im Breisgau, Halle, Jena, Kirchheim unter Teck
2026-11-09
Not yet open
Intraoperative Application of Cold Atmospheric Plasma to Prevent Postoperative Wound Complications in the Inguinal Region of High-risk Patients With Peripheral Arterial Occlusive Disease
NCT07571408Peripheral Occlusive Disease, Wound Healing, Wound Healing Complication, Cold Atmospheric Plasma
Ursula Werra
Not applicable
214
Cologne
2026-11-01
Not yet open
Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial
NCT07840456Carcinoma, Squamous Cell of Head and Neck HNSCC
DrugsRuxolitinib·Pembrolizumab
University Hospital, Basel, Switzerland
Phase 2
66
Würzburg, Greifswald, Cologne, Hagen, Hamburg
2026-11
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
850
Gerlingen, Ulm, Wangen, Munich, Regensburg, Frankfurt am Main, Oldenburg, Cologne
2026-09-30
Not yet open
External Beam Radiotherapy Combined With Endorectal High-dose-rate Brachytherapy in Elderly and Frail Patients With Rectal Cancer
NCT06729645Rectal Cancer
University Hospital of Cologne
Not applicable
80
Kempten, Frankfurt am Main, Cologne, Leipzig
2026-09-30
Recruiting
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
NCT07412704Arthritis, Rheumatoid
Bristol-Myers Squibb
Phase 1/2
84
München, Berlin, Cologne, Herne, Sendenhorst
2026-09-15
Not yet open
Catheter Ablation for AF in Patients With Severe Mitral Regurgitation After Successful Transcatheter Mitral-Valve Repair
NCT07380932Atrial Fibrillation (AF), Mitral Valve (MV) Regurgitation
Atrial Fibrillation Network
Not applicable
956
Cologne, Frankfurt, Hamburg, Münster
2026-09-01
Not yet open
Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP)
NCT07721649Acute Coronary Syndrome, Heart Failure, Influenza, Human, Cardiovascular Diseases
Stephan Baldus
Not applicable
482
Cologne, Hamburg
2026-09
Not yet open
Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial
NCT07788586Candidemia, Invasive Candidiasis
Oliver Cornely, MD
Phase 4
420
Aachen, Berlin, Cologne, Dresden, Düsseldorf, Frankfurt am Main, Freiburg im Breisgau, Giessen
2026-09
Recruiting
Stratification and Treatment in Early Psychosis Study - ENHANCE
NCT06778564Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode
University of Oxford
Phase 3
250
Augsburg, Berlin, Cologne, Munich
2026-09
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsImzokitug·Vedolizumab·Infliximab·Pumitamig
Bristol-Myers Squibb
Phase 2
160
Stuttgart, Marburg, Homburg, Cologne, Haile, Hessen
2026-08-31
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Bad Oldesloe, Bamberg, Berlin, Bielefeld, Bochum, Bremen, Chemnitz, Cologne
2026-08-24
Recruiting
PULSed Field Ablation for Atrial Fibrillation Using a Balloon for Early Intervention - Study
NCT07621003Atrial Fibrillation
Asklepios proresearch
Not applicable
264
Bad Oeynhausen, Cologne, Düsseldorf, Frankfurt, Giessen, Hamburg, Herne, Leipzig
2026-08-19
Recruiting
Pivotal Study of N-acetyl-L-leucine for CACNA1A
NCT07221292CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
Cologne
2026-08-17
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Aachen, Berlin, Cologne, Dresden, Erlangen, Essen, Hamburg, Hanover
2026-08-05
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc
DrugsEtoposide·Atezolizumab·Carboplatin
SystImmune Inc.
Phase 3
550
Cologne, Essen, Halle
2026-08-04
Not yet open
Modulated Mid-frequency Whole-body Electromyostimulation and Nutritional Therapy in Gastrointestinal Cancer Patients
NCT06414122Oesophageal Cancer, Gastric Cancer, Duodenal Cancer, Colorectal Cancer
University of Cologne
Not applicable
88
Cologne
2026-08-01
Recruiting
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
NCT07549698Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura
DrugZugo-cel
CRISPR Therapeutics AG
Phase 1/2
60
Cologne, Hannover, Hanover, Mainz
2026-07-17
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
DrugsObrixtamig·Etoposide·Carboplatin
Boehringer Ingelheim
Phase 3
390
Berlin, Bonn, Cologne, Dresden, Düsseldorf, Erlangen, Freiburg im Breisgau, Hamburg
2026-07-10
Recruiting
A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.
NCT07672236Head & Neck Cancer, Oral Mucositis
OncoZenge AB
Phase 3
150
Cologne, Frankfurt am Main, Freiburg im Breisgau, Kiel, Tübingen
2026-07-07
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109Type 2 Diabetes Mellitus
DrugsElecoglipron·Dapagliflozin
AstraZeneca
Phase 3
2,000
Berlin, Cologne, Damme, Deggingen, Duisburg, Essen, Falkensee, Frankfurt
2026-07-06
Recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07365241Small Cell Lung Cancer
DrugsABBV-706·Amrubicin·Lurbinectedin·Topotecan
AbbVie
Phase 3
531
Würzburg, Kassel, Cologne
2026-07-02
Active, closed
Artificial Intelligence(AI) in the Emergency Department (ED) in Cologne
NCT07725965Emergency Care, Clinical Decision Support, Triage
University of Cologne
Observational
100,000
Cologne
2026-07-01
Not yet open
Preoperative Physical Exercise, Nutritional Support, and Psychological Intervention (Multimodal Prehabilitation) to Strengthen Patients' Overall Health and Reduce Postoperative Complications
NCT07389746Cancer Surgery, Prehabilitation
University Hospital of Cologne
Not applicable
400
Cologne
2026-07-01
Not yet open
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma
NCT07507968Esophagogastric Adenocarcinoma
DrugDurvalumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
101
Berlin, Cologne, Essen, Frankfurt am Main, Göttingen, Halle, Hamburg, Heidelberg
2026-07-01
Recruiting
Evaluation of an Exercise Intervention During Intensive Medical Treatment in Pediatric Oncology.
NCT07647471Pediatric Cancer Patients
Universität Duisburg-Essen
Not applicable
346
Berlin, Bonn, Cologne, Essen, Frankfurt, Hamburg, Jena, Mainz
2026-07-01
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
DrugElecoglipron
AstraZeneca
Phase 3
4,500
Bad Oeynhausen, Bochum, Cologne, Dresden, Falkensee, Gera, Hamburg, Leipzig
2026-06-29
Recruiting
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
NCT07764978Newly Diagnosed Multiple Myeloma
DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab
AstraZeneca
Phase 3
750
Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Hamburg, Kiel, Leipzig
2026-06-26
Active, closed
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugsCliramitug·Eplontersen
AstraZeneca
Phase 2
326
Berlin, Cologne, Essen, Hamburg, Heidelberg, Homburg, München, Münster
2026-06-11
Recruiting
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
NCT07486817Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Pemetrexed·Cisplatin·Carboplatin
Boehringer Ingelheim
Phase 2
60
Cologne, Heidelberg
2026-06-04
Recruiting
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
NCT07519902Persistent Corneal Epithelial Defect
DrugCenegermin
Dompé Farmaceutici S.p.A
Phase 3
150
Erlangen, Frankfurt am Main, Marburg, Cologne, Düsseldorf, Homburg, Berlin
2026-06-02
Recruiting
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
117
Tübingen, Giessen, Cologne
2026-06-01
Not yet open
An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function
NCT07613398Congenital Heart Diseases, Cardiac Diseases
Matthias Stuber
Observational
300
Bonn, Cologne, Berlin
2026-06
Not yet open
Stratification and Treatment in Early Psychosis Study -ASSIST
NCT07326124Treatment Resistant Psychosis, Psychosis
University of Oxford
Phase 3
250
Berlin, Cologne, Munich
2026-06
Not yet open
Evaluation of iNstroke Aspiration Catheters for Thrombectomy: a Multi-center Prospective Study
NCT07376447Acute Ischemic Stroke
iVascular S.L.U.
Not applicable
160
Bremen, Cologne, Dortmund, Hamburg, Nuremberg
2026-05-31
Recruiting
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
NCT07645443Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
Stephanie Mehl
Not applicable
252
Mannheim, Augsburg, München, Hamburg, Marburg, Cologne, Berlin
2026-05-27
Recruiting
A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma
NCT07353099Thrombotic Thrombocytopenic Purpura (TTP)
Takeda
Observational
50
Bonn, Cologne, Jena, Leipzig, München
2026-05-26
Recruiting
BIO|STREAM.CSP Study
NCT07393009Cardiac Pacing, Cardiac Pacemaker, Implantable Cardioverter Defibrillator, Cardiac Resynchronization Therapy Devices
Biotronik SE & Co. KG
Observational
1,000
Bad Krozingen, Bad Nauheim, Bad Oeynhausen, Cologne, Osnabrück
2026-05-25
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
5,700
Mannheim, Muehldorf Am Inn, Munich, Weiden in Der Oberpfalz, Frankfurt am Main, Hanover, Cologne, Essen
2026-05-11
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
5,610
Aachen, Bad Friedrichshall, Bad Oeynhausen, Berlin, Bochum, Coburg, Cologne, Dresden
2026-05-11
Recruiting
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT07611110Metastatic Castration-resistant Prostate Cancer
DrugsFPI-2265·Xofigo·Cabazitaxel·Zytiga
AstraZeneca
Phase 3
670
Augsburg, Berlin, Bonn, Cologne, Dresden, Essen, Jena, Karlsruhe
2026-05-04
Recruiting
Glycolytic Phenotype (vLapeak) and Magnitude of Skeletal Muscle Hypertrophy After Resistance Training
NCT07721766Healthy Volunteers, Muscle Hypertrophy, Glycolysis, Moderately Trainend
Technical University of Munich
Not applicable
120
München, Cologne, Düsseldorf, Chemnitz, Leipzig
2026-05-04
Not yet open
Stratification and Treatment in Early Psychosis Study - PROMOTE
NCT07434973Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
DrugCannabidiol
University of Oxford
Phase 3
586
Berlin, Cologne, Lübeck, München
2026-05-01
Recruiting
Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support
NCT07655479Cardiogenic Shock Post Myocardial Infarction
University Hospital of Cologne
Observational
115
Düsseldorf, Kiel, Cologne
2026-04-23
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Cologne, Giessen, Greifswald, Hamburg, Hanover, Munich
2026-04-23
Recruiting
Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
NCT07788729Cancer, Lung Cancer, Colorectal Cancer, Hematological Cancer
University of Regensburg
Not applicable
384
Augsburg, Erlangen, Regensburg, Würzburg, Bayreuth, Berlin, Cologne
2026-04-21
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Berlin, Cologne, Essen, Frankfurt am Main
2026-04-17
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
DrugINCB161734
Incyte Corporation
Phase 3
588
Berlin, Bochum, Bonn, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2026-04-09
Recruiting
A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
NCT06792994Chronic Lymphocytic Leukemia
German CLL Study Group
Observational
2,000
Cologne, Ulm
2026-04-02
Recruiting
Improved Management of Patients With Recent-Onset Stable Chest Pain
NCT07476040Coronary Artery Disease (CAD)
Philipps University Marburg
Not applicable
3,369
Augsburg, Bad Neustadt an der Saale, Berlin, Cologne, Düsseldorf, Erlangen, Frankfurt, Giessen
2026-04-01
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
DrugApecotrep
Boehringer Ingelheim
Phase 2
132
Berlin, Cologne, Hamburg, Hanover, Mainz, München
2026-03-23
Recruiting
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
NCT07366086Osteogenesis Imperfecta
Amgen
Phase 3
71
Cologne, Würzburg
2026-03-18
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
DrugsPumitamig·Yervoy·Ipilimumab
Bristol-Myers Squibb
Phase 1/2
198
Cologne, Lübeck, Frankfurt, Mainz
2026-03-16
Recruiting
Neonatal Data and Biobank to Study Factors Influencing Development in Preterm Infants Born at <32 Weeks' Gestation and/or <1500 g Birth Weight
NCT07490912Preterm Infant Development, Preterm Infant Health, Prematurity Complications, Premature Birth
University Hospital of Cologne
Observational
1,300
Cologne
2026-03-13
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Pembrolizumab
Bristol-Myers Squibb
Phase 3
750
Wangen, Landshut, Rosenheim, Kaiserslautern, Langen, Wiesbaden, Cologne, Dortmund
2026-03-12
Recruiting
Clinical Performance and Safety Assessment of the Use of iCover Balloon Expandable Covered Stent (iVascular) Implanted as Bridging Stent in FEVAR (Fenestrated Endovascular Aortic Repair) for the Treatment of Complex Abdominal Aortic Aneurysms
NCT07529275Complex Abdominal Aortic Aneurysms
iVascular S.L.U.
Not applicable
165
Cologne, Hamburg, Leipzig, München
2026-02-16
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
DrugApecotrep
Boehringer Ingelheim
Phase 3
286
Berlin, Cologne, Hamburg, Hanover, Heidelberg, Leipzig, Mainz, Würzburg
2026-02-16
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546HIV Infections
DrugsVH4524184·Dovato·Dolutegravir/Lamivudine
ViiV Healthcare
Phase 2
186
Berlin, Cologne, Frankfurt, Hamburg, München
2026-02-11
Recruiting
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
NCT07392372HIV -1 Infection
BioNTech SE
Phase 1
67
Cologne, Mannheim
2026-02-09
Active, closed
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
240
Cologne
2026-02-09
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
1,980
Cologne, Dresden, Duisburg, Essen, Hamburg, Leipzig, Lingen, Mainz
2026-02-06
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
Tübingen, Cologne, Berlin
2026-01-22
Recruiting
Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
NCT07025824AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome)
DrugsTreosulfan·Melphalan·Fludarabine
Technische Universität Dresden
Phase 2
220
Aachen, Augsburg, Berlin, Chemnitz, Cologne, Dresden, Frankfurt am Main, Greifswald
2026-01-21
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab
Boehringer Ingelheim
Phase 3
400
Berlin, Cologne, Esslingen am Neckar, Frankfurt, Gauting, Großhansdorf, Heidelberg, Oldenburg
2026-01-16
Recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901Obesity With Diabetes, Overweight With Diabetes
DrugRibupatide
Kailera
Phase 3
1,156
Tübingen, Falkensee, Cologne, Essen, Oldenburg in Holstein, Schwerin
2026-01-12
By invitation
Lead Evaluation for Defibrillation and Reliability Post Approval Study
NCT07005232Tachyarrhythmia
Medtronic
Observational
2,000
Bielefeld, Cologne, Meerbusch
2026-01-07
Recruiting
Blood Flow Restriction Training in Acute Geriatric Rehabilitation
NCT07291765Sarcopenia in Elderly
University Hospital, Bonn
Not applicable
60
Cologne
2026-01-01
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
DrugsTersolisib·Exemestane·Anastrozole·Ribociclib
Eli Lilly and Company
Phase 3
800
Berlin, Bottrop, Cologne, Dessau, Donauwörth, Dresden, Düsseldorf, Erlangen
2025-12-22
Active, closed
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
360
Löwenstein, Frankfurt am Main, Giessen, Cologne
2025-12-22
Recruiting
Vit-A-Vision® Clinical Investigation
NCT06596733Burning Eye, Irritation; Eyeball, Tired Eye, Dry Eye Disease
OmniVision GmbH
Not applicable
77
Cologne
2025-12-19
Active, closed
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850Obesity and Overweight
DrugBerobenatide
Pfizer
Phase 3
3,578
Munich, Leipzig, Bad Homburg, Berlin, Cologne, Dresden, Essen, Hamburg
2025-12-19
Recruiting
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875Obesity, Overweight
DrugRibupatide
Kailera
Phase 3
2,340
Tübingen, Falkensee, Cologne, Essen, Dresden, Leipzig, Oldenburg in Holstein, Hamburg
2025-12-18
Recruiting
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
NCT07314164Neuroendocrine Tumors
Ipsen
Observational
150
Aschaffenburg, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dresden, Erlangen
2025-12-17
Recruiting
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
NCT07280585Polycystic Kidney, Autosomal Dominant
DrugDapagliflozin
University of Cologne
Phase 3
420
Stuttgart, Nuremberg, Aachen, Berlin, Cologne, Dortmund, Dresden, Düsseldorf
2025-12-16
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Bad Saarow, Bielefeld, Bonn, Cologne, Dresden, Duisburg, Düsseldorf, Erlangen
2025-12-12
Recruiting
BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF
NCT07181590Paroxysmal AF, Atrial Arrhythmia, Atrial Fibrillation, Persistent Atrial Fibrillation
Abbott Medical Devices
Not applicable
300
Bad Oeynhausen, Cologne, Hamburg, München
2025-12-11
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer
DrugsTelisotuzumab Adizutecan·Osimertinib
AbbVie
Phase 2/3
490
Heidelberg, Würzburg, Marburg, Cologne, Jena, Hamburg
2025-12-10
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213Clostridioides Difficile Infection
AstraZeneca
Phase 2
230
Augsburg, Berlin, Cologne, Frankfurt, Hamburg, Jena, Leipzig, München
2025-12-10
Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945Chronic Kidney Disease
DrugDapagliflozin
Boehringer Ingelheim
Phase 3
120
Cologne, Hamburg, Heidelberg, Tübingen
2025-12-09
Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802Plaque Psoriasis
DrugZasocitinib
Takeda
Phase 3
110
Bad Bentheim, Cologne, Münster, Bonn, Mainz
2025-12-04
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Observational
380
Aschaffenburg, Bielefeld, Bochum, Chemnitz, Cologne, Düsseldorf, Essen, Hamburg
2025-12-03
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
DrugsIDRX-42·Sunitinib
GlaxoSmithKline
Phase 3
450
München, Cologne, Essen, Dresden, Berlin, Mannheim, Tübingen
2025-12-03
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
7,140
Cologne, Essen, Goch, Hamburg, Oldenburg, Stuhr
2025-12-01
Recruiting
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
NCT07281833Breast Cancer, HR-positive Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
DrugCapivasertib
Women's Cancer Study Group GmbH
Phase 3
250
Cologne, Essen, Mönchengladbach, Münster, Frankfurt, Hamburg, Hildesheim, München
2025-11-27
Recruiting
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
111
Giessen, Cologne, Tübingen
2025-11-19
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Erlangen, Göttingen, Cologne, Berlin
2025-11-19
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Incorporated
Phase 2
26
Berlin, Cologne
2025-11-19
Active, closed
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
1,060
Erlangen, Berlin, Bonn, Cologne, Dresden, Homburg/Saar, Jena, Leipzig
2025-11-12
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Bonn, Sulzbach, Cologne, Giessen, Mainz, München, Münster, Tübingen
2025-11-10
Recruiting
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT07015242Lymphoma
DrugsProcarbazine·Breyanzi·Calcium folinate·Temozolomide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Freiburg im Breisgau, Ulm, Cologne, Essen, Chemnitz, Berlin, Göttingen, Hamburg
2025-11-06
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
Esslingen am Neckar, Stuttgart, Donauwörth, Oldenburg, Cologne, Chemnitz, Kiel, Berlin
2025-11-05
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
DrugsDato-DXd·Docetaxel
AstraZeneca
Phase 3
400
Bad Saarow, Bielefeld, Bonn, Cologne, Essen, Frankfurt, Freiburg im Breisgau, Gauting
2025-10-31
Recruiting
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
NCT06934967Paroxysmal Nocturnal Hemoglobinuria (PNH)
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
12
Cologne, Berlin
2025-10-28
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Abraxane·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
München, Frankfurt am Main, Göttingen, Bochum, Chemnitz, Dresden, Berlin, Cologne
2025-10-23
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan
Eli Lilly and Company
Phase 3
1,630
Aachen, Berlin, Bonn, Cologne, Dresden, Düsseldorf, Erlangen, Essen
2025-10-22
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
DrugNNC6019-0001
Novo Nordisk A/S
Phase 3
1,280
Bad Oeynhausen, Berlin, Cologne, Dresden, Frankfurt am Main, Freiburg im Breisgau, Jena, Kiel
2025-10-02
Recruiting
#AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.
NCT06900829HIV Infection, HIV, Stigma, Education
Casper Rokx
Not applicable
5,200
Berlin, Cologne, München
2025-10-01
Recruiting
Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers
NCT06855134Rare Cancer
German Cancer Research Center
Observational
946
Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg
2025-09-29
Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
DrugZilebesiran
Alnylam Pharmaceuticals
Phase 3
11,000
Aachen, Ahaus, Altenburg, Bad Homburg, Berlin, Brandenburg an der Havel, Bremen, Cologne
2025-09-22
Recruiting
Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps
NCT06765226Heart Failure
Abiomed Inc.
Observational
200
Heidelberg, Düsseldorf, Dresden, Leipzig, Berlin, Cologne, Essen
2025-09-21
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
400
Berlin, Bonn, Braunschweig, Bremen, Cologne, Düsseldorf, Essen, Freiburg im Breisgau
2025-09-13
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
DrugsErdafitinib·Mitomycin C·Gemcitabine
Janssen Research & Development, LLC
Phase 3
220
Cologne, Herne, Leverkusen, Mannheim, Nürtingen, Regensburg
2025-09-10
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
DrugsNavlimetostat·Iza-bren
Bristol-Myers Squibb
Phase 2
182
München, Frankfurt am Main, Halle, Cologne, Würzburg
2025-09-09
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsTacabrutideg·Pirtobrutinib
BeOne Medicines
Phase 3
500
Bochum, Bonn, Cologne, Dortmund, Karlsruhe, Lübeck, Stuttgart, Ulm
2025-09-04
Not yet open
Immune-Marker Platform for Patients With Advanced Lung Cancer
NCT07150598NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV, NSCLC Non-small Cell Lung Cancer
Technische Universität Dresden
Observational
500
Cologne, Dresden
2025-09-01
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT06925321Invasive Mold Infections
DrugFosmanogepix
Basilea Pharmaceutica
Phase 3
234
Ulm, Cologne, Mainz, Frankfurt
2025-08-26
Recruiting
An International Observational Study of Adults With Acute Infection
NCT07069400Infectious Disease
University of Minnesota
Observational
1,500
Cologne
2025-08-25
Recruiting
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
NCT06995573Alzheimer Disease
NSC-Therapeutics
Phase 1/2
90
Altenburg, Bad Homburg, Cologne, Göttingen, Mannheim, Ratingen
2025-08-25
Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
NCT06959524Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
Boston Scientific Corporation
Not applicable
1,616
Cologne, Lahr, Trier
2025-08-21
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin
Amgen
Phase 3
350
Chemnitz, Cologne, Dresden, Essen, Frankfurt am Main, Gauting, Großhansdorf, Kiel
2025-08-18
Recruiting
SCORE Study: Comparing Surgery and Rigid Collar Treatment for Odontoid Fractures in Adults Over 70
NCT06961578Odontoid Fracture, Elderly
Technical University of Munich
Not applicable
322
Munich, Frankfurt am Main, Berlin, Aachen, Cologne, Dresden, Essen, Göttingen
2025-08-13
Recruiting
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
NCT07264426Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
DrugEfgartigimod PH20
argenx
Observational
200
Berlin, Bochum, Cologne, Düsseldorf, Frankfurt, Giessen, Göttingen, Hamburg
2025-08-11
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/Prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Augsburg, Berlin, Braunschweig, Cologne, Dresden, Duisburg, Düsseldorf, Essen
2025-08-06
Not yet open
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
NCT06045195Hodgkin Lymphoma
DrugPembrolizumab
University of Cologne
Phase 2
40
Cologne
2025-08
Recruiting
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 2
60
Cologne, Homburg, Magdeburg
2025-07-30
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
Munich, Göttingen, Bad Homburg, Chemnitz, Cologne, Ulm
2025-07-21
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Cologne, Düsseldorf, Leipzig, München
2025-07-16
Recruiting
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
NCT07013474COVID-19 Infection
DrugsIbuzatrelvir·Veklury·Remdesivir
Pfizer
Phase 3
300
München, Cologne, Hamburg, Rostock, Trier, Villingen-Schwenningen, Wuppertal
2025-07-14
Active, closed
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT07015983Lupus Erythematosus, Systemic, Lupus Nephritis
DrugsZola-cel·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Leipzig, Magdeburg, Berlin, Cologne, Erlangen, Herne
2025-07-14
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903Transthyretin Amyloidosis With Cardiomyopathy
DrugNucresiran
Alnylam Pharmaceuticals
Phase 3
1,750
Berlin, Cologne, Dresden, Göttingen, Hanover, Heidelberg, Leipzig, Magdeburg
2025-07-02
Active, closed
Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options
NCT06794554Chronic Pulmonary Aspergillosis
Mundipharma Research Limited
Phase 2
60
Berlin, Cologne, Gauting
2025-06-30
By invitation
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
NCT07073014Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 3
140
Homburg, Cologne, Magdeburg
2025-06-20
Recruiting
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
NCT06972446Rheumatoid Arthritis
DrugsABBV-8736·ABBV-701·Lutikizumab·Adalimumab
AbbVie
Phase 2
180
Wetzlar, Bonn, Cologne, Hamburg
2025-06-20
Active, closed
A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
NCT07048197Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 1/2
27
Freiburg im Breisgau, Göttingen, Cologne, Berlin, Ulm
2025-06-20
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax
BeOne Medicines
Phase 3
630
Berlin, Cologne, Dresden, Jena, Kiel, Mutlangen, München, Neubrandenburg
2025-06-11
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
DrugVerducatib
Boehringer Ingelheim
Phase 3
1,755
Aachen, Ahrensburg, Bamberg, Berlin, Bochum, Bonn, Cologne, Donaustauf
2025-06-09
Recruiting
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06902558Autosomal Dominant Polycystic Kidney Disease
Calico Life Sciences LLC
Phase 2
240
Heidelberg, Munich, Hanover, Cologne, Berlin
2025-06-09
Active, closed
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542Chronic Graft-versus-host-disease
DrugAxatilimab
Incyte Corporation
Phase 3
9
Aachen, Berlin, Cologne, Dresden, Erlangen, Frankfurt am Main, Freiburg im Breisgau, Göttingen
2025-06-04
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Azacitidine·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Augsburg, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel
2025-06-04
Recruiting
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT06961006Malignant Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
160
Heidelberg, Frankfurt am Main, Cologne, Essen, Hamburg
2025-05-29
Recruiting
A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System (STRIDE II)
NCT06747117Lower Extremity Acute Limb Ischemia, LE ALI
Penumbra Inc.
Observational
300
Cologne, Leipzig, Stuttgart
2025-05-18
Active, closed
Study of GS-0151 in Participants With Rheumatoid Arthritis
NCT06902519Rheumatoid Arthritis
Gilead Sciences
Phase 1
65
Cologne, Hamburg, München
2025-05-14
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Nürtingen, Stuttgart, Munich, Nuremberg, Frankfurt am Main, Cologne, Duisburg, Lübeck
2025-05-13
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD5492
AstraZeneca
Phase 1
72
Cologne, Erlangen, Magdeburg
2025-05-01
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
974
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin
Mirati Therapeutics Inc.
Phase 3
630
Esslingen am Neckar, Ulm, München, Frankfurt am Main, Giessen, Hanover, Oldenburg, Cologne
2025-04-24
Active, closed
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
NCT06928142Sjogren Disease
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
83
Freiburg im Breisgau, Cologne, Hamburg, München
2025-04-23
Active, closed
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145Hypertension, Pulmonary
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
440
Heidelberg, München, Giessen, Cologne, Mainz, Dresden, Berlin
2025-04-16
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Cologne, Dresden, Essen, Hamburg, Hanover, Heidelberg, Koblenz, Langen
2025-04-09
Recruiting
The Dragon PLC Trial (DRAGON-PLC)
NCT06914648Primary Liver Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Maastricht University
Not applicable
358
Cologne, Dresden, Hanover
2025-04-01
Not yet open
Pre-Operative Treatment in REseCTable COlon CanceR
NCT06899477Colo-rectal Cancer, Colon Cancer, Colon Carcinoma
DrugsMFOLFOXIRI·MFOLFOX6·Folfox·Irinotecan
Dominik Paul Modest
Phase 3
714
Berlin, Berlin-Spandau, Chemnitz, Cologne, Dessau, Dortmund, Frankfurt, Hamburg
2025-04
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Berlin, Chemnitz, Cologne, Donauwörth, Erfurt, Gauting, Georgsmarienhütte, Großhansdorf
2025-03-27
Recruiting
Vaccine-induced Immunity in Immunocompromised Patients
NCT06612515Immunodeficiency
University of Cologne
Observational
1,000
Cologne
2025-03-25
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsEfti·Pemetrexed·Keytruda·Paclitaxel
Immutep S.A.S.
Phase 3
756
Amberg, Augsburg, Bad Saarow, Berlin, Cologne, Frankfurt, Frankfurt am Main, Gauting
2025-03-21
Active, closed
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
NCT06673056Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
Cologne, Giessen
2025-03-18
Not yet open
Early Recovery After Surgery (ERAS)/Prehabilitation - Randomized Controlled Trial on the Implementation of ERAS/prehabilitation in Elective Reconstructive Shoulder Surgery
NCT06868472Rotator Cuff
Prof. Arasch Wafaisade
Not applicable
84
Cologne
2025-03-18
Recruiting
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
NCT06854640Sepsis, Coagulopathy
DrugBAY3389934
Bayer
Phase 1
36
München, Cologne, Dresden, Leipzig
2025-03-12
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis
DrugZugo-cel
CRISPR Therapeutics
Phase 1
80
Augsburg, Cologne, Hanover, Mainz
2025-03-10
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623Non Small Cell Lung Carcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin
AbbVie
Phase 1/2
252
Freiburg im Breisgau, Heilbronn, Augsburg, Würzburg, Frankfurt am Main, Cologne, Hemer, Oldenburg in Holstein
2025-03-06
Recruiting
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
NCT06806033Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
DrugsGlofitamab·Obinutuzumab·Oxaliplatin·Gemcitabine
Hoffmann-La Roche
Phase 2
130
Berlin, Cologne, Magdeburg
2025-03-05
Recruiting
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
NCT06796907Tumours, Gynecological
DrugsMo-Rez·Dostarlimab·Bevacizumab
GlaxoSmithKline
Phase 1/2
305
Cologne, Leipzig, Mainz, München
2025-03-04
By invitation
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
NCT06823115Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors
Indiana University
Observational
4,000
Cologne
2025-03-01
Recruiting
S-ICD Implantation: US Based Pilot Study
NCT06771700Sudden Cardiac Death
Universitätsklinikum Köln
Not applicable
20
Cologne
2025-03-01
Recruiting
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
NCT06764706Ulcerative Colitis
AbbVie
Observational
200
Heidelberg, Potsdam, Tostedt, Hanover, Schwerin, Ahaus, Bochum, Cologne
2025-02-27
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin
Bristol-Myers Squibb
Phase 3
530
Frankfurt am Main, Oldenburg, Cologne, Halle, Bad Berka, Gauting, Großhansdorf, Heidelberg
2025-02-25
Recruiting
Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock
NCT05726825Septic Shock
Hannover Medical School
Not applicable
274
Berlin, Bonn, Braunschweig, Bremerhaven, Cologne, Erlangen, Essen, Halle
2025-02-19
Recruiting
FMRI-neurofeedback in Parkinson's Disease
NCT06582355Parkinson Disease
Maastricht University Medical Center
Not applicable
60
Cologne
2025-02-10
Recruiting
Cyclosporine In Takotsubo Syndrome
NCT05946772Takotsubo Cardiomyopathy
DrugCyclosporine A
University Hospital Heidelberg
Phase 2
204
Bad Nauheim, Berlin, Bonn, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2025-02-01
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Cologne, Homburg, Kiel, Mainz, München, Würzburg
2025-01-30
Recruiting
Colorectal Resections in Patients With Retroperitoneal Sarcoma
NCT06943612Sarcoma, Soft Tissue, Retroperitoneal Sarcoma
Heidelberg University
Observational
120
Mannheim, Göttingen, Berlin, Cologne, Dresden, Erlangen, Greifswald, Halle
2025-01-27
Recruiting
Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal Dystrophy
NCT06425666Cataract Surgery, Cataract and Fuchs Endothelial Corneal Dystrophy
University of Cologne
Not applicable
120
Cologne
2025-01-24
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126Melanoma, Cutaneous Malignant
DrugsAnzu-cel·Lifileucel·Temodar·Dacarbazine
Immatics US, Inc.
Phase 3
360
Cologne, Berlin, Bonn, Dresden, Erlangen, Essen, Frankfurt am Main, Hamburg
2025-01-14
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
750
Berlin, Cologne, Dresden, Freiburg im Breisgau, Hamburg, Herne, Langenau, Ratingen
2025-01-09
Recruiting
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
NCT06807359Prostate Cancer
DrugVerteporfin
SpectraCure AB
Phase 1/2
43
Cologne, Rostock
2025-01-06
Recruiting
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugPirtobrutinib
Loxo Oncology, Inc.
Phase 2
249
Cologne, Frankfurt, Göttingen, Hanover, Hösbach, Koblenz
2025-01-03
Active, closed
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
NCT06747572Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Incorporated
Observational
401
Berlin, Cologne
2024-12-19
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Cologne, Leipzig, Jena, Aachen, Hamburg, Mainz, Nuremberg, Ulm
2024-12-17
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Jena, Lübeck, Chemnitz, Cologne, Dresden, Hamburg, Hanover, Mainz
2024-12-16
Recruiting
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
NCT06557798Aortic Valve Stenosis
The Leeds Teaching Hospitals NHS Trust
Observational
550
Bad Nauheim, Bad Oeynhausen, Berlin, Cologne, Dortmund, Dresden, Düsseldorf, Frankfurt
2024-12-12
Active, closed
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
NCT06734234Kidney Disease
GlaxoSmithKline
Phase 1
86
Cologne, Lübeck
2024-12-11
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858Candidemia, Candidiasis, Invasive
DrugsCaspofungin·Fosmanogepix·Fluconazole
Basilea Pharmaceutica
Phase 3
450
Ulm, Regensburg, Frankfurt am Main, Giessen, Cologne, Heidelberg
2024-12-11
Recruiting
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
NCT06679140COVID-19 SARS-CoV-2 Infection
DrugIbuzatrelvir
Pfizer
Phase 3
2,330
Munich, Frankfurt am Main, Obertshausen, Cologne, Augsburg, Berlin, Freiburg im Breisgau, Hamburg
2024-12-08
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
655
Cologne, Dresden, Erlangen, Freiburg im Breisgau, Hamburg, Hanover, Herne, München
2024-12-04
Recruiting
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
NCT06607757CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
DrugsCapivasertib·Fulvestrant
GBG Forschungs GmbH
Phase 2
120
Augsburg, Berlin, Bielefeld, Bremen, Cologne, Cottbus, Dortmund, Essen
2024-12-04
Active, closed
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805HIV Infections
DrugsRpv La·Cabotegravir·B/F/TAF
ViiV Healthcare
Phase 3
326
Cologne, Berlin, Düsseldorf, Frankfurt
2024-12-02
Recruiting
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
NCT06667700Coronavirus Disease (COVID-19)
DrugMolnupiravir
Merck Sharp & Dohme LLC
Phase 3
3,082
Munich, Frankfurt am Main, Cologne, Berlin
2024-12-02
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt
2024-11-27
Active, closed
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742Wet Age Related Macular Degeneration, wAMD
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Cologne
2024-11-27
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Berlin, Cologne, Dessau, Dresden, Freiburg im Breisgau, Greifswald, Herne, Jena
2024-11-21
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Essen, Esslingen am Neckar
2024-11-18
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Berlin, Bochum, Cologne, Dresden, Frankfurt, Heidelberg, Homburg, Landshut
2024-11-12
Recruiting
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
NCT06531499Metastatic Castration-Resistant Prostate Cancer
DrugLu-PSMA
Novartis Pharmaceuticals
Phase 1
106
Cologne, Wuppertal, Aachen, Berlin, Essen, München, Rostock
2024-11-11
Active, closed
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383Obesity
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
800
Villingen-Schwenningen, Lingen, Cologne, Essen, Leipzig, Oldenburg in Holstein, Hamburg
2024-11-01
Recruiting
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
NCT06669117Solid Tumor, MET Alteration
Pierre Fabre Medicament
Phase 1/2
140
Cologne, Dresden
2024-10-22
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Cologne, Essen, München, Rostock
2024-10-15
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Berlin, Bochum, Cologne, Dresden, Erlangen, Frankfurt, Heidelberg, Homburg
2024-10-14
Recruiting
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
NCT05460000Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma
North Eastern German Society of Gynaecological Oncology
Phase 2
640
Aachen, Baden-Baden, Berlin, Bonn, Cologne, Detmold, Dortmund, Dresden
2024-10-11
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
NCT06630286HIV-1-infection
DrugsISL/LEN·B/F/TAF
Gilead Sciences
Phase 3
609
Berlin, Bonn, Cologne, Essen, Hamburg
2024-10-09
By invitation
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
NCT06419179Small Cell Lung Carcinoma
DrugsOlaparib·Durvalumab
University of Cologne
Phase 2
29
Cologne
2024-10-09
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
NCT06630299HIV-1-Infection
DrugsAntiretroviral Combinations·ISL/LEN
Gilead Sciences
Phase 3
600
Cologne, Hanover, Mannheim, München
2024-10-08
Recruiting
Efficacy of INM004 in Children With STEC-HUS
NCT06389474Hemolytic-Uremic Syndrome
Inmunova S.A.
Phase 3
220
Berlin, Cologne, Heidelberg
2024-10-05
Recruiting
Hair Cortisol as Marker of Chronic Stress in Preterm and Term Fathers - Fathair-study
NCT05969431Stress, Psychological, Father-Child Relations, Premature Birth
University of Cologne
Observational
120
Cologne
2024-10-01
Recruiting
Investigation of the Audible ICD Alert Tone
NCT06388382Implantable Defibrillator User
Universitätsklinikum Köln
Observational
150
Cologne
2024-10-01
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Adagrasib·Sotorasib
Hoffmann-La Roche
Phase 3
338
Berlin, Cologne, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Heidelberg, Hemer
2024-09-23
Active, closed
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163Systemic Lupus Erythematosus
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 2
190
München, Cologne
2024-09-17
Recruiting
Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis
NCT06488625Ulcerative Colitis, Unspecified
University Hospital Schleswig-Holstein
Phase 2/3
459
Kiel, Aachen, Augsburg, Bamberg, Berlin, Bremen, Cologne, Dachau
2024-09-12
Recruiting
Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl
NCT06498349Parkinson Disease, Impulse Control Disorders
University of Kiel
Not applicable
60
Cologne, Dresden, Düsseldorf, Hamburg, Kiel, Marburg, Mitte, Tübingen
2024-09-05
Recruiting
STIMPulseControl Ancillary Speech Study
NCT06561919Parkinson Disease, Impulse Control Disorder
Steffen Paschen
Not applicable
60
Cologne, Dresden, Düsseldorf, Hamburg, Kiel, Marburg, Mitte, Tübingen
2024-09-05
Active, closed
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
179
Stuttgart, Frankfurt am Main, Cologne, Leipzig, Jena, Essen, Lübeck, Mainz
2024-09-04
Recruiting
ATLAS (AltaValve) Pivotal Trial
NCT06465745Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation
4C Medical Technologies, Inc.
Not applicable
450
Berlin, Bonn, Cologne, Dortmund, Mainz, Oeynhausen, Trier, Ulm
2024-09-03
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801Pulmonary Arterial Hypertension
DrugSeralutinib
Gossamer Bio USA, Inc.
Phase 3
330
Cologne, Dresden, Giessen, Heidelberg, Munich, München, Würzburg
2024-09-03
Not yet open
Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment
NCT06497322Breast Cancer, Triple Negative Breast Cancer
University Hospital of Cologne
Not applicable
60
Cologne
2024-09-01
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation
DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin
Bayer
Phase 3
555
Stuttgart, Nuremberg, Frankfurt am Main, Giessen, Cologne, Essen, Hemer, Berlin
2024-08-28
Active, closed
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498Multiple Myeloma
DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib
Kite, A Gilead Company
Phase 3
452
Berlin, Cologne, Essen, Freiburg im Breisgau, Hamburg, Leipzig, München, Tübingen
2024-08-23
Recruiting
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
NCT06440993Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA
DrugsDurvalumab·Gemcitabine·Cisplatin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
42
Aachen, Bonn, Cologne, Düsseldorf, Frankfurt, Göttingen, Hanover, Lübeck
2024-08-23
Recruiting
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
NCT05583071Non-Hodgkin Lymphoma
DrugsTafasitamab·Methotrexate·Lenalidomide·Rituximab
University of Cologne
Phase 2
20
Stuttgart, Freiburg im Breisgau, Cologne, Hamburg, Essen, Berlin
2024-08-23
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Cologne, Frankfurt, Gauting, Großhansdorf, Hamburg, Heidelberg, Mainz, Münster
2024-08-22
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
Tübingen, Cologne, Münster, Berlin
2024-08-16
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine
AstraZeneca
Phase 3
620
Berlin, Bonn, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2024-08-12
Active, closed
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
NCT06534892Respiratory Syncytial Virus Infections
DrugRSVPreF3 OA vaccine
GlaxoSmithKline
Phase 3
10,212
Weinheim, Munich, Freiberg, Berlin, Cologne, Dachau, Dippoldiswalde, Dresden
2024-08-01
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
DrugsSaruparib·Camizestrant·Exemestane·Anastrozole
AstraZeneca
Phase 3
788
Aachen, Augsburg, Berlin, Cologne, Dessau, Düsseldorf, Erlangen, Göttingen
2024-08-01
Recruiting
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
NCT05373264ADPKD
DrugHydrochlorothiazide
University Medical Center Groningen
Phase 3
300
Berlin, Cologne, Dresden, Leipzig
2024-07-31
Active, closed
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616Alzheimer Disease
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Aachen, Cologne, Homburg, Münster
2024-07-22
Active, closed
Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study
NCT06149650Chronic Limb-Threatening Ischemia
Cardiovascular and Interventional Radiological Society of Europe
Observational
400
Cologne, Essen, Hanover, Heilbronn, Karlsruhe, Mülheim, Neumünster, Rendsburg
2024-07-15
Recruiting
NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
NCT06494540Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
AstraZeneca
Observational
600
Bad Homburg, Berlin, Bremen, Celle, Chemnitz, Cologne, Deggendorf, Frankfurt
2024-06-28
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
10,000
Bad Berka, Berlin, Bielefeld, Bremen, Cologne, Dachau, Dortmund, Dresden
2024-06-25
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Würzburg, Frankfurt am Main, Hanover, Aachen, Cologne, Mainz, Homburg, Berlin
2024-06-25
Active, closed
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
NCT06455059Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 3
80
Cologne, Magdeburg
2024-06-17
Active, closed
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06223516Multiple Myeloma
DrugEtentamig
AbbVie
Phase 1
60
Frankfurt am Main, Cologne, Hamburg
2024-06-17
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505Ovarian Cancer, Non-small Cell Lung Cancer
DrugTUB-040
Tubulis GmbH
Phase 1/2
250
Berlin, Cologne
2024-06-12
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Cologne, Dresden, Essen, Gauting, Großhansdorf, Heidelberg, Münster, Würzburg
2024-06-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,200
Pforzheim, München, Ulm, Hanover, Lüneburg, Rostock, Cologne, Duisburg
2024-06-05
Recruiting
Next-Generation-Sequencing Approach to Neutropenic Sepsis
NCT05815628Febrile Neutropenia
Boris Böll
Observational
400
Cologne, Dessau, Essen, Frankfurt am Main, Leipzig, Magdeburg
2024-06-05
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277Obesity, Weight Gain
DrugTirzepatide
Eli Lilly and Company
Phase 3
300
Cologne, Leipzig, Ulm
2024-06-03
Recruiting
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
NCT04837859Classical Hodgkin Lymphoma
DrugTislelizumab
University of Cologne
Phase 2
120
Cologne
2024-05-24
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
550
Cologne, Leipzig
2024-05-21
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Frankfurt am Main, Cologne, Berlin
2024-05-20
Active, closed
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
NCT06294925Colitis, Ulcerative
DrugEtrasimod
Pfizer
Observational
360
Freiburg im Breisgau, Kassel, Aachen, Andernach, Berlin, Cologne, Dachau, Frankfurt am Main
2024-05-08
Recruiting
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NCT06508775Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma
DrugsMB-CART19.1·Zamtocabtagene autoleucel
Miltenyi Biomedicine GmbH
Not applicable
40
Berlin, Cologne, Erlangen, Göttingen, Münster, Tübingen, Würzburg
2024-05-05
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
DrugsDato-DXd·Osimertinib
AstraZeneca
Phase 3
582
Berlin, Cologne, Erfurt, Frankfurt, Göttingen, Immenhausen, Kiel, Mainz
2024-04-29
Active, closed
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT05972551Osteogenesis Imperfecta
DrugRomosozumab
Amgen
Phase 3
111
Cologne, Würzburg
2024-04-22
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820Non-Muscle Invasive Bladder Neoplasms
DrugGemcitabine
Janssen Research & Development, LLC
Phase 3
641
Berlin, Braunschweig, Cologne, Dresden, Frankfurt am Main, Hamburg, Herne, Jena
2024-04-18
Recruiting
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
NCT06137378Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III, Laryngeal Squamous Cell Carcinoma Stage IV
DrugsKeytruda·Pembrolizumab
University of Leipzig
Phase 2
140
Mannheim, Ulm, München, Regensburg, Würzburg, Potsdam, Cologne, Leipzig
2024-04-17
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsRilvegostomig·Dato-DXd·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
675
Berlin, Bonn, Cologne, Düsseldorf, Essen, Freiburg im Breisgau, Gauting, Georgsmarienhütte
2024-04-11
Recruiting
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
NCT05791409CLL/SLL
DrugsEpcoritamab·Venetoclax
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 1/2
112
Berlin, Cologne, Freiburg im Breisgau, Greifswald, Münster, Stuttgart, Ulm
2024-04-10
Recruiting
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
NCT05871021Glioblastoma
University Hospital Tuebingen
Phase 2
146
Augsburg, Cologne, Frankfurt, Freiburg im Breisgau, Leipzig, Mannheim, Munich, Regensburg
2024-04-10
Active, closed
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764Non-Muscle Invasive Bladder Neoplasms
DrugsTAR-200·Mitomycin C·Gemcitabine
Janssen Research & Development, LLC
Phase 3
272
Cologne, Halle, Leverkusen, Lübeck, Mettmann, München
2024-04-09
Recruiting
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML
NCT05904106Acute Myeloid Leukemia
DrugsGemtuzumab Ozogamicin·Azacitidine·Venetoclax
Technische Universität Dresden
Phase 2
146
Essen, Aachen, Augsburg, Chemnitz, Cologne, Dresden, Erlangen, Frankfurt am Main
2024-04-07
Recruiting
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
NCT06274515Breast Cancer
Hoffmann-La Roche
Phase 4
320
Cologne, Essen, Karlsruhe, Mannheim, Ulm
2024-04-02
Active, closed
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
NCT06333808HIV-1-infection
DrugsBictegravir·Lenacapavir·B/F/TAF
Gilead Sciences
Phase 3
577
Aachen, Berlin, Cologne, Frankfurt, Hamburg, Munich, München
2024-03-25
Recruiting
Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
NCT05944016Chronic Kidney Failure in Children and Young Adults
DrugDapagliflozin
University Hospital Goettingen
Phase 3
102
Heidelberg, München, Hamburg, Frankfurt am Main, Göttingen, Cologne, Münster, Leipzig
2024-03-25
Recruiting
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
NCT05904119First Progression of Glioblastoma
DrugLomustine
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
411
Bochum, Cologne, Erlangen, Essen, Heidelberg, Leipzig, Munich, Regensburg
2024-03-15
By invitation
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
NCT05932615Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder
Abbott Medical Devices
Not applicable
1,500
Dortmund, Bad Nauheim, Cologne, Frankfurt, Kiel, München, Ulm
2024-03-15
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414Oligometastatic Prostate Cancer (OMPC)
DrugsPiflufolastat·Lu-PSMA
Novartis Pharmaceuticals
Phase 3
450
Munich, Cologne, Aachen, Augsburg, Berlin, Essen, Münster, Rostock
2024-03-12
Recruiting
Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
NCT04838652Classical Hodgkin Lymphoma
DrugPembrolizumab
University of Cologne
Phase 2
29
Cologne
2024-03-05
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
17,300
Aachen, Bad Friedrichshall, Bad Homburg, Berlin, Bielefeld, Cologne, Dresden, Essen
2024-03-05
Active, closed
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173Alzheimer Disease
Acumen Pharmaceuticals
Phase 2
542
Berlin, Cologne, Mannheim, Munich
2024-02-29
Active, closed
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
NCT05925530Non-small Cell Lung Cancer
DrugDurvalumab
AstraZeneca
Phase 2
142
Berlin, Cologne, Großhansdorf, Moers, Würzburg
2024-02-22
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311HIV, HIV Infections
DrugsBictegravir·Emtricitabine·Dolutegravir·Lamivudine
ViiV Healthcare
Phase 3
307
Berlin, Cologne, Frankfurt, Hamburg, München
2024-02-21
Active, closed
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
NCT06380738Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Observational
111
Aschaffenburg, Augsburg, Bergisch Gladbach, Berlin, Bonn, Cologne, Dresden, Duisburg
2024-02-14
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin
Boehringer Ingelheim
Phase 3
428
Augsburg, Berlin, Cologne, Dresden, Giessen, Heidelberg, Oldenburg, Tübingen
2024-02-09
Recruiting
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
NCT05902169Glioblastoma, Recurrent Glioblastoma, GBM
DrugsLomustine·Temodal·Temozolomide·Carboplatin
CarThera
Phase 3
560
Berlin, Chemnitz, Cologne, Dresden, Essen, Münster
2024-01-29
Recruiting
Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS
NCT06553625Parkinson Disease, Dystonia, Essential Tremor, Movement Disorders
Boston Scientific Corporation
Observational
200
Cologne, Düsseldorf, Würzburg
2024-01-29
Active, closed
Early Genetic Identification of Obesity
NCT06239064Obesity, Childhood, Hyperphagia, Retinopathy, Syndactyly
Rolfs Consulting und Verwaltungs-GmbH (RCV)
Observational
1,000
Aachen, Augsburg, Bad Krozingen, Bielefeld, Bonn, Bückeburg, Cologne, Essen
2024-01-24
Active, closed
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891Chronic Graft Versus Host Disease
DrugsBelumosudil·Prednisolone·Prednisone
Sanofi
Phase 3
260
Berlin, Cologne, Dresden, Freiburg im Breisgau, Hamburg, Kiel, Münster, Regensburg
2024-01-23
Recruiting
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06153251Relapsed and/or Refractory Multiple Myeloma
DrugsFludara·Cytoxan·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Cologne, Heidelberg, Würzburg
2024-01-23
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
NCT06079398Achondroplasia
DrugNavepegritide
Ascendis Pharma A/S
Phase 2
72
Berlin, Cologne
2024-01-23
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
DrugsAZD3470·Keytruda·Pembrolizumab
AstraZeneca
Phase 1/2
161
Berlin, Cologne, Erlangen, Würzburg
2024-01-23
Active, closed
Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment
NCT05533242Glioblastom WHO Grade 4
University Hospital Muenster
Phase 1
10
Cologne, Essen, Münster, Würzburg
2024-01-22
Active, closed
Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)
NCT06181240Coronary Artery Disease, Coronary Artery Calcification
Bolt Medical
Not applicable
426
Bad Segeberg, Cologne, Dortmund
2024-01-19
Active, closed
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337Metastatic Breast Cancer
DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel
DualityBio Inc.
Phase 3
541
Erlangen, Wiesbaden, Bottrop, Cologne, Witten, Dresden, Berlin
2024-01-18
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Berlin, Cologne, Dresden, Frankfurt am Main, Heidelberg, Immenhausen, Moers
2024-01-18
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Berlin, Cologne, Essen, Giessen, Hamburg, Hanover, Heidelberg, Homburg
2024-01-11
Recruiting
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
NCT05949125Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
AvenCell Europe GmbH
Phase 1
37
Ulm, Munich, Würzburg, Marburg, Dresden, Berlin, Cologne, Essen
2024-01-03
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Berlin, Cologne, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Halle, Hamburg
2023-12-29
Active, closed
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
NCT06140836Carcinoma, Non-Small-Cell Lung
DrugsRepotrectinib·Crizotinib
Bristol-Myers Squibb
Phase 3
190
Esslingen am Neckar, Würzburg, Oldenburg, Berlin, Cologne, Dresden, Gauting, Immenhausen
2023-12-21
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
1,264
Berlin, Chemnitz, Cologne, Donauwörth, Erfurt, Freiburg im Breisgau, Gauting, Georgsmarienhütte
2023-12-21
Recruiting
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
NCT05512364ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
220
Aachen, Augsburg, Bergisch Gladbach, Bottrop, Bremen, Cologne, Dresden, Hanover
2023-12-15
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Bamberg, Cologne, Düsseldorf, Erlangen, Essen, Freiburg im Breisgau, Heidelberg, Homburg/Saar
2023-12-11
Active, closed
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
DrugBel-sar
Aura Biosciences
Phase 3
108
Berlin, Cologne, Essen, Hamburg, Lübeck, München, Tübingen
2023-12-06
Active, closed
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
NCT05689671Non-Small Cell Lung Cancer Metastatic
DrugsAbraxane·Tecentriq·Atezolizumab·Nab-paclitaxel
Nikolaj Frost MD
Phase 4
136
Amberg, Augsburg, Bad Homburg, Berlin, Bielefeld, Cologne, Dresden, Essen
2023-12-06
Active, closed
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
NCT05993234HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma
DrugTrastuzumab deruxtecan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
257
Aschaffenburg, Berlin, Cologne, Essen, Göppingen, Hamburg, Hanover, München
2023-12-05
Recruiting
The Viability Control of Human Endothelial Cells Before Keratoplasty (V-CHECK) Study
NCT05847387Corneal Transplant Failure, Corneal Endothelial Cell Loss
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Observational
135
Cologne, Münster
2023-12-01
Recruiting
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Hamilton Health Sciences Corporation
Not applicable
4,000
Karlsruhe, Darmstadt, Frankfurt am Main, Rostock, Bad Oeynhausen, Cologne, Kaiserslautern, Leipzig
2023-11-30
Recruiting
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
NCT06212947Hypochondroplasia
BioMarin Pharmaceutical
Observational
400
Cologne, Magdeburg
2023-11-27
Recruiting
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943Lymphatic Malformations
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2/3
232
Freiburg im Breisgau, Mannheim, Cologne, Leipzig, Berlin, Ulm
2023-11-24
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate
AstraZeneca
Phase 3
1,898
Bergisch Gladbach, Berlin, Braunschweig, Cologne, Dresden, Duisburg, Frankfurt, Frankfurt am Main
2023-11-21
Recruiting
Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]
NCT05870566Corneal Transplantation
Claus Cursiefen
Not applicable
110
München, Cologne, Düsseldorf, Homburg, Berlin, Freiburg im Breisgau, Rostock
2023-11-20
Active, closed
The PEERLESS II Study
NCT06055920Pulmonary Embolism
Inari Medical
Not applicable
1,200
Augsburg, Bad Krozingen, Berlin, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2023-11-17
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
DrugsElironrasib·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
534
Cologne, Esslingen am Neckar, Moers, Nuremberg
2023-11-14
Active, closed
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT05870579Breast Cancer
DrugsGa-NeoB·Lu-NeoB·Ribociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1
28
Cologne
2023-11-13
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
DrugsVolrustomig·Yervoy·Paraplatin·Opdivo
AstraZeneca
Phase 3
863
Berlin, Bochum, Cologne, Essen, Gauting, Georgsmarienhütte, Großhansdorf, Hamburg
2023-11-09
Active, closed
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555Melanoma
DrugsOpdivo·Nivolumab
Amgen
Phase 3
633
Frankfurt am Main, Marburg, Cologne
2023-11-02
Not yet open
Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial
NCT06115629Esophageal Cancer, Gastric Cancer
University of Dublin, Trinity College
Phase 3
952
Cologne
2023-11
Active, closed
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332Metastatic Uveal Melanoma
DrugsDarovasertib·Crizotinib·Dacarbazine·Yervoy
IDEAYA Biosciences
Phase 2/3
420
Heidelberg, Cologne, Essen, Dresden, Berlin
2023-10-31
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
612
Freiburg im Breisgau, Würzburg, Ludwigshafen, Cologne, Dresden, Berlin, Erlangen, Hanover
2023-10-27
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,057
Freiburg I. Breisgau, Wangen I. Allgaeu, Munich, Münnerstadt, Immenhausen, Stralsund, Essen, Cologne
2023-10-25
Recruiting
GENERATE - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications
NCT05867927GYN Disorders
Intuitive Surgical
Observational
1,250
Hamburg, Wiesbaden, Berlin, Bochum, Coburg, Cologne, Essen, Frankfurt am Main
2023-10-25
Active, closed
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326Adenocarcinoma, Pancreatic Ductal
DrugsAutogene cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab
Genentech, Inc.
Phase 2
260
Berlin, Bochum, Cologne, Dresden, Essen, Frankfurt, Hamburg, Heidelberg
2023-10-18
Active, closed
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806Multiple Myeloma
DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan
Celgene
Phase 3
79
Heidelberg, Ulm, Nuremberg, Cologne, Leipzig, Dresden, Essen, Hamburg
2023-10-16
Active, closed
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083Multiple Myeloma
DrugsCilta-cel·Bortezomib·Daratumumab·Lenalidomide
Stichting European Myeloma Network
Phase 3
759
Cologne, Hamburg, Leipzig, Tübingen, Würzburg
2023-10-10
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
Aachen, Berlin, Cologne, Darmstadt, Deggendorf, Dessau, Düsseldorf, Essen
2023-10-05
Recruiting
Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment
NCT06033274Tricuspid Regurgitation
Montefiore Medical Center
Observational
800
Munich, Frankfurt am Main, Essen, Lübeck, Bad Oeynhausen, Cologne, Hamburg
2023-10-05
Active, closed
German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa
NCT06095713Fabry Disease
DrugPegunigalsidase-alfa
Universität Münster
Observational
60
Berlin, Cologne, Hamburg, Hanover, Mainz, Müllheim, Münster, Würzburg
2023-10-01
Recruiting
Post-Market Clinical Follow Up Study With Navitor Valve
NCT06008080Aortic Stenosis
Abbott Medical Devices
Observational
1,000
Bad Bevensen, Berlin, Cologne, Dortmund, Erlangen, Frankfurt, Hamburg, Kiel
2023-09-29
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone
Hoffmann-La Roche
Phase 3
1,130
Berlin, Brandenburg an der Havel, Chemnitz, Cologne, Düsseldorf, Erlangen, Essen, Frankfurt
2023-09-18
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,255
Freiburg I. Breisgau, Munich, Münnerstadt, Hamburg, Immenhausen, Marburg, Essen, Cologne
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Minden, Mainz, Cologne, Düsseldorf, Tübingen
2023-09-13
Active, closed
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
DrugsZola-cel·Tocilizumab·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
270
Würzburg, Cologne, Leipzig, Magdeburg, Berlin, Düsseldorf, Erlangen
2023-09-13
Active, closed
Avacostar - (PASS)
NCT05897684ANCA-associated Vasculitis
Vifor Fresenius Medical Care Renal Pharma
Observational
507
Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Göttingen, Hamburg, Hanover
2023-09-11
Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171Glomerulonephritis Rapidly Progressive
DrugsCyclophosphamid·Rituximab
Alentis Therapeutics AG
Phase 2
80
Berlin, Cologne, Dresden, Essen, Hanover, Leipzig, Lübeck, München
2023-09-07
Active, closed
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398Metastatic Castrate-sensitive Prostate Cancer
DrugApalutamide
Janssen Research & Development, LLC
Phase 3
420
Aachen, Augsburg, Cologne, Dresden, Lübeck, München, Nürtingen, Würzburg
2023-08-31
Recruiting
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
NCT03463954Malignant Neoplasm of Breast
Novian Health Inc.
Not applicable
122
Cologne
2023-08-09
Active, closed
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610Primary IgA Nephropathy
Hoffmann-La Roche
Phase 3
459
Leipzig, Aachen, Berlin, Cologne, Hanover, Mainz, Stuttgart, Villingen-Schwenningen
2023-08-08
Recruiting
Continuous Delivery Room Skin-to-skin-study for Moderate and Late Preterm Infants
NCT05975203Preterm Birth, Mother-Infant Interaction, Infant Development
University of Cologne
Not applicable
60
Cologne
2023-08-04
Recruiting
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
NCT05538806Pleural Mesothelioma
NovoCure Ltd.
Observational
198
Gauting, Regensburg, Harburg, Bremen, Göttingen, Dresden, Berlin, Cologne
2023-08-01
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
DrugUpadacitinib
AbbVie
Phase 3
1,014
Cologne, Mainz, Dresden, Buch, Frankfurt am Main
2023-07-25
Active, closed
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,089
Mannheim, Augsburg, München, Göttingen, Rostock, Cologne, Essen, Minden
2023-07-19
Recruiting
Regulation of Extracellular Sodium in End Stage Renal Disease Upon Volume and Electrolyte Challenges
NCT06408077Hyponatremia
University of Cologne
Not applicable
60
Cologne
2023-07-01
Recruiting
Mechanisms Of Disease Progression in Aortic Stenosis - the MODAS Study
NCT05851209Aortic Stenosis, Imaging, Pathogenesis, Disease Progression
Heinrich-Heine University, Duesseldorf
Observational
938
Bonn, Cologne, Düsseldorf
2023-07-01
Active, closed
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
NCT05883644Advanced Hepatocellular Carcinoma
DrugsTremelimumab·Durvalumab
AstraZeneca
Phase 3
111
Berlin, Cologne, Frankfurt, Lübeck
2023-06-27
Recruiting
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
NCT05807932Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
DrugsMycophenolate Mofetil·Ara-C·Tacrolimus·Venetoclax
Heinrich-Heine University, Duesseldorf
Phase 1/2
38
Aachen, Düsseldorf, Cologne, Frankfurt, Jena, München
2023-06-26
Recruiting
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
NCT05701358Acute Myocardial Infarction, Coronary Artery Disease
Population Health Research Institute
Not applicable
5,100
Cologne, Dachau, Frankfurt, Hamburg, Heide
2023-06-22
Recruiting
Prospective Köln Bonn Registry for the Extraction of Pacmaker and ICD Leads
NCT06597578Infections, Pacemaker, Artificial, Defibrillators, Implantable
Evangelic Hospital Kalk Cologne
Observational
200
Cologne
2023-06-04
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan
Amgen
Phase 3
509
Berlin, Cologne, Dresden, Essen, Gauting, Großhansdorf, Stuttgart, Würzburg
2023-05-31
Active, closed
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC)
NCT05597761COVID-19, Adult, Immunocompromised Patients
Oliver Cornely, MD
Observational
49
Aachen, Cologne, Essen
2023-05-15
Active, closed
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
288
Freiburg im Breisgau, Cologne, Leipzig, Herne, Mainz
2023-04-21
Active, closed
ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System
NCT05686317Heart Failure
Edwards Lifesciences
Not applicable
100
Bad Oeynhausen, Cologne, Dresden, Heidelberg, Mainz
2023-04-01
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
DrugsTAR-200·Cetrelimab
Janssen Research & Development, LLC
Phase 3
1,135
Cologne, Duisburg, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Markkleeberg, Mettmann
2023-03-23
Recruiting
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
NCT05259605Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Observational
1,650
Bochum, Bonn, Cologne, Essen, Frankfurt, Jena, Leipzig, Regensburg
2023-03-21
Active, closed
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
NCT06039241Atopic Dermatitis
Sanofi
Observational
572
Aachen, Ahaus, Andernach, Berlin, Braunschweig, Buxtehude, Chemnitz, Cologne
2023-03-07
Recruiting
A Multicentric Cohort and Biomarker Study for Improved Care of Patients with Extrapulmonary Tuberculosis
NCT06875336Extrapulmonary Tuberculosis
University of Cologne
Observational
150
Bonn, Borstel, Cologne, Frankfurt, Hamburg, Heidelberg
2023-03-06
Active, closed
A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.
NCT05637112Systemic Lupus Erythematosus
AstraZeneca
Observational
551
Heidelberg, Erlangen, Bad Bramstedt, Schleswig-Holstein, Greifswald, Cologne, D Sseldorf, Herne
2023-02-27
Recruiting
Brain-Oscillation-Synchronized Stimulation to Enhance Motor Recovery in Early Subacute Stroke
NCT05600374Ischemic Stroke, Acute
University Hospital Tuebingen
Not applicable
144
Frankfurt a.M., Cologne, Münster, Tübingen
2023-02-06
Active, closed
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219Primary Immune Thrombocytopenia
DrugsEltrombopag·Ianalumab
Novartis Pharmaceuticals
Phase 3
152
Cologne, Dresden, Jena
2023-02-02
Recruiting
Dietary Interventions During Living Kidney Donations
NCT05709600Living-Kidney Donors
University of Cologne
Not applicable
80
Cologne
2023-02-01
Recruiting
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258Autosomal Recessive Polycystic Kidney (ARPKD)
DrugTolvaptan
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
20
Cologne
2023-01-23
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562H3 K27M, Glioma
DrugDordaviprone
Jazz Pharmaceuticals
Phase 3
510
Heidelberg, Augsburg, Regensburg, Frankfurt am Main, Bonn, Cologne, Essen, Berlin
2023-01-23
Active, closed
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
516
Tübingen, Munich, Dresden, Lübeck, Chemnitz, Cologne, Erlangen, Planegg
2023-01-12
Active, closed
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Carfilzomib·Dexamethasone
Bristol-Myers Squibb
Phase 3
606
Ulm, Munich, Hanover, Dortmund, Kiel, Jena, Berlin, Cologne
2023-01-10
Recruiting
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
NCT06019130Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms, Nasopharynx Cancer
DrugsAvonex·Opdivo·Adrucil·Nivolumab
German Society for Pediatric Oncology and Hematology GPOH gGmbH
Phase 2
57
Aachen, Berlin, Bielefeld, Bonn, Cologne, Cottbus, Dortmund, Dresden
2023-01-10
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Medtronic Cardiovascular
Not applicable
600
Augsburg, Cologne, Essen, Frankfurt, Leipzig, Munich, Münster
2023-01-05
Recruiting
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
NCT05306041HER2-positive Breast Cancer
DrugsPhesgo·Inavolisib
GBG Forschungs GmbH
Phase 2
170
Essen, Augsburg, Berlin, Bielefeld, Chemnitz, Cologne, Dessau, Dresden
2023-01-02
Recruiting
Laparoscopic Implantation of a Gastric Pacemaker in the Treatment of Gastroparesis
NCT06661668Gastroparesis, Gastroparesis Postoperative, Gastroparesis Nondiabetic, Gastroparesis With Diabetes Mellitus
Evangelic Hospital Kalk Cologne
Observational
50
Cologne
2023-01-01
Recruiting
DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device
NCT05543447Intracranial Aneurysm, Flow Diverter
Acandis GmbH
Observational
158
Augsburg, Berlin, Bremerhaven, Cologne, Dresden, Düsseldorf, Essen, Frankfurt am Main
2022-12-15
Active, closed
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT05581303Atherosclerotic Cardiovascular Disease
DrugOlpasiran
Amgen
Phase 3
7,297
Aachen, Bad Krozingen, Bad Oeynhausen, Berlin, Bremen, Cologne, Dresden, Essen
2022-12-14
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
DrugTozorakimab
AstraZeneca
Phase 3
3,527
Augsburg, Berlin, Cologne, Hamburg, Hanover, Kiel, Leverkusen, Marburg
2022-12-13
Active, closed
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314Carcinoma, Non-Small-Cell Lung
DrugsCapmatinib·Amivantamab
Janssen Research & Development, LLC
Phase 1/2
57
Berlin, Chemnitz, Cologne, Dresden, Essen, Münster
2022-12-13
Active, closed
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351Severe Hypertriglyceridemia
DrugOlezarsen
Ionis Pharmaceuticals, Inc.
Phase 3
885
Berlin, Cologne, Dresden, Witten
2022-12-13
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654Triple Negative Breast Cancer
DrugsXeloda·Sacituzumab Govitecan·Keytruda·Capecitabine
Gilead Sciences
Phase 3
1,514
Augsburg, Berlin, Bielefeld, Bottrop, Braunschweig, Bremen, Cologne, Dortmund
2022-12-12
Active, closed
TARGET Study: Safety and Performance of the Cardiovalve TR Replacement System
NCT05486832Tricuspid Regurgitation
Cardiovalve Ltd.
Not applicable
157
Bad Oeynhausen, Berlin, Bonn, Cologne, Hamburg, Lübeck, Regensburg
2022-12-09
Recruiting
Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer
NCT05652348Gastric Cancer, Colon Cancer, Peritoneal Carcinomatosis
Technische Universität Dresden
Observational
48
Berlin, Cologne, Dresden, Ulm, Würzburg
2022-12-08
Recruiting
GMMG Multiple Myeloma Registry
NCT07111884Multiple Myeloma
Prof. Dr. Hartmut Goldschmidt
Observational
999
Berlin, Bielefeld, Bochum, Bonn, Chemnitz, Cologne, Darmstadt, Düsseldorf
2022-12-08
By invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
DrugEplontersen
Ionis Pharmaceuticals, Inc.
Phase 3
1,400
Cologne, Heidelberg, Homburg, Münster, Würzburg
2022-11-30
Active, closed
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
NCT05331183Cystic Fibrosis
DrugsELX/TEZ/IVA·Ivacaftor·Elexacaftor/Tezacaftor/Ivacaftor
Vertex Pharmaceuticals Incorporated
Phase 3
297
Berlin, Cologne, Essen, Frankfurt, Giessen, Halle, Hanover, Jena
2022-11-23
Active, closed
RESPONDER-HF Trial
NCT05425459Heart Failure, Heart Failure, Diastolic
Corvia Medical
Not applicable
750
Bad Krozingen, Bad Nauheim, Berlin, Cologne, Dresden, Düsseldorf, Freiburg im Breisgau, Göttingen
2022-11-17
Recruiting
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428Carcinoma, Non-small-Cell Lung
DrugsLMWH·Direct Anticoagulant·DOAC·Low molecular weight heparin
Janssen Research & Development, LLC
Phase 2
520
Berlin, Cologne, Grosshandorf, Immenhausen, Würzburg
2022-11-11
Active, closed
Xeltis Hemodialysis Access Graft: aXess Pivotal Study
NCT05473299End-stage Renal Disease
Xeltis
Not applicable
120
Cologne
2022-11-04
Active, closed
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
NCT05535244Multiple Myeloma
DrugsCevostamab·Tocilizumab
Hoffmann-La Roche
Phase 1/2
90
Cologne, Hamburg, Würzburg
2022-10-17
Recruiting
Evaluation of Volume and Electrolyte Balance in Hyponatremia Treatment - a Prospective Observational Trial
NCT05692726Non-hypervolemic Hyponatremia
University of Cologne
Observational
50
Cologne
2022-10-15
Active, closed
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320Multiple Myeloma
DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone
Janssen Research & Development, LLC
Phase 3
864
Berlin, Cologne, Hamburg, Heidelberg, Leipzig, Mainz, Würzburg
2022-10-13
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed
Gilead Sciences
Phase 3
1,021
Cologne, Essen, Großhansdorf, Halle, Hamburg, Hemer, Karlsruhe, Lübeck
2022-10-12
Recruiting
VRAP-Heart - Virtual Reality Assisted Patient Empowerment for Interventions in Structural Heart Disease
NCT05552352Severe Aortic Valve Stenosis
Heinrich-Heine University, Duesseldorf
Not applicable
300
Düsseldorf, Cologne
2022-10-05
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Augsburg, Berlin, Bottrop, Cologne, Dessau, Donauwörth, Dortmund, Düsseldorf
2022-10-04
Recruiting
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
NCT05443126NSCLC
DrugPemetrexed
Ellipses Pharma
Phase 1/2
265
Berlin, Cologne, München
2022-09-30
Active, closed
The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events
NCT05421286HIV-1-infection, Inflammation, AIDS
Rigshospitalet, Denmark
Observational
991
Bonn, Cologne, Eppendorf, Frankfurt am Main, Hamburg
2022-09-28
Recruiting
Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma
NCT05564091Primary Open Angle Glaucoma
Nova Eye, Inc.
Not applicable
78
Bonn, Cologne, Dortmund
2022-09-08
Active, closed
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
DrugSonrotoclax
BeOne Medicines
Phase 1/2
125
Cologne, Düsseldorf
2022-09-05
By invitation
Outcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment
NCT05825898Tricuspid Regurgitation
Ottawa Heart Institute Research Corporation
Observational
3,500
Bad Oeynhausen, Berlin, Bonn, Cologne, Frankfurt, Hamburg, Leipzig, Mainz
2022-09-01
Recruiting
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms
DrugsElacestrant·Abemaciclib
Stemline Therapeutics, Inc.
Phase 1/2
73
Bayreuth, Cologne, Dresden, Düsseldorf, Erlangen, Hanover, Leipzig, Worms
2022-08-31
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
240
Munich, Ludwigshafen, Frankfurt am Main, Braunschweig, Cologne, Berlin, Mainz
2022-08-10
Active, closed
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
NCT05371080Herpes Zoster
GlaxoSmithKline
Phase 3
3,038
Wangen, Weinheim, Rednitzhembach, Wallerfing, Flörsheim, Cologne, Essen, Goch
2022-08-10
Active, closed
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214Sjogren Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
506
Cologne, Dresden, Berlin, Hanover, Herne
2022-08-04
Recruiting
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
NCT05410145KRAS P.G12C
DrugsD3S-001·Cetuximab·Pemetrexed·Cisplatin
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
Cologne, Hamburg
2022-08-03
Active, closed
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286Triple Negative Breast Cancer, PD-L1 Positive
DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel
Gilead Sciences
Phase 3
443
Berlin, Bonn, Bottrop, Cologne, Erlangen, Essen, Freiburg im Breisgau, Hamburg
2022-07-25
Recruiting
Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy
NCT05442710Sepsis, Severe
Artcline GmbH
Phase 2
142
Freiburg im Breisgau, Regensburg, Bonn, Cologne, Aue, Leipzig, Halle, Kiel
2022-07-24
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
703
Berlin, Cologne, Dachau, Dresden, Duisburg, Erlangen, Essen, Frankfurt
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Ulm, Cologne
2022-07-21
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine
Gilead Sciences
Phase 3
623
Berlin, Bonn, Cologne, Essen, Hamburg, Heidelberg, Lübeck, Mannheim
2022-07-20
Recruiting
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
NCT05475925LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
DrugDibotatug
Dren Bio
Phase 1/2
200
Berlin, Cologne, Leipzig
2022-07-13
Active, closed
Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)
NCT05062291Venous Stenosis, Venous Occlusion
Merit Medical Systems, Inc.
Observational
500
Berlin, Cologne
2022-06-23
Recruiting
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
NCT05142189Non-Small Cell Lung Cancer
DrugsBNT116·Gotistobart·Cemiplimab·Osimertinib
BioNTech SE
Phase 1
320
Cologne, Frankfurt, Hamburg, Mainz
2022-06-17
Active, closed
Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome
NCT05382156Endogenous Cushing's Syndrome
DrugOsilodrostat
RECORDATI GROUP
Observational
206
Berlin, Cologne, Düsseldorf, Frankfurt, Hamburg, Munich, Oldenburg, Würzburg
2022-06-13
Recruiting
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626Locally Advanced Solid Tumor, Metastatic Solid Tumor
DrugsNeladalkib·Repaglinide·Itraconazole·Midazolam
Nuvalent Inc.
Phase 1/2
840
Cologne, Frankfurt, Großhansdorf, Heidelberg
2022-06-09
Active, closed
AMP SCZ® Observational Study: PREDICT-DPACC
NCT05905003Clinical High Risk, Psychosis, Remission, Conversion
Brigham and Women's Hospital
Observational
2,617
Cologne, Jena, Munich
2022-06-02
Active, closed
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
NCT05186974Non-small Cell Lung Cancer
DrugsSacituzumab Govitecan·Paraplatin·Keytruda·Cisplatin
Gilead Sciences
Phase 2
193
Berlin, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt, Gauting, Großhansdorf, Halle
2022-05-30
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
DrugRepagermanium
Dimerix Bioscience Pty Ltd
Phase 3
286
Aachen, Cologne, Dresden, Hamburg, Hanover, Lübeck, Mainz, Villingen-Schwenningen
2022-05-30
Active, closed
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257Limited-Stage Small Cell Lung Cancer
DrugsCarboplatin/cisplatin-etoposide·Serplulimab
Shanghai Henlius Biotech
Phase 3
511
Cologne, Travemünde
2022-05-17
Recruiting
Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence
NCT04976153Fecal Incontinence
Innovacell GmbH
Phase 3
290
Cologne, Mannheim
2022-05-11
Recruiting
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
NCT05090891Fibrodysplasia Ossificans Progressiva (FOP)
DrugZilurgisertib
Incyte Corporation
Phase 2
98
Cologne
2022-05-05
Active, closed
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
NCT05174650Intrahepatic Cholangiocarcinoma
DrugsTecentriq·Atezolizumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
27
Bad Saarow, Berlin, Bonn, Cologne, Esslingen am Neckar, Frankfurt, Hanover, Krefeld
2022-04-20
Recruiting
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
NCT05197192Chronic Lymphocytic Leukemia
DrugsVenclyxto·Acalabrutinib·Venclexta·Obinutuzumab
German CLL Study Group
Phase 3
202
Bad Saarow, Berlin, Bremen, Cologne, Dortmund, Düsseldorf, Eschweiler, Essen
2022-04-19
Active, closed
Olorofim Aspergillus Infection Study
NCT05101187Invasive Aspergillosis
DrugAmbisome
F2G Biotech GmbH
Phase 3
225
Leipzig, Berlin, Cologne, Hamburg-Eppendorf
2022-03-31
Active, closed
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT05270668Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
DrugTulisokibart
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
154
Freiburg im Breisgau, Bad Nauheim, Hohenfelde B Bad Doberan, Cologne
2022-03-29
Recruiting
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT04895436Chronic Lymphocytic Leukemia (CLL)
DrugsVenclexta·Obinutuzumab·Venetoclax
AbbVie
Phase 2
75
Mutlangen, Ulm, Landshut, Munich, Rostock, Cologne, Homburg, Dresden
2022-03-28
Active, closed
TRICuspid Intervention in Heart Failure Trial
NCT04634266Heart Failure Attributable to Severe Tricuspid Regurgitation
LMU Klinikum
Not applicable
360
Bad Oeynhausen, Berlin, Bernau, Bonn, Bremen, Cologne, Dortmund, Düsseldorf
2022-03-25
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
DrugsMosunetuzumab·Venclyxto·Venclexta·Tocilizumab
Hoffmann-La Roche
Phase 1
332
Augsburg, Cologne, Ulm
2022-03-07
Active, closed
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
NCT05153226Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS
DrugCyclophosphamide
DKMS gemeinnützige GmbH
Phase 3
640
Aachen, Augsburg, Chemnitz, Cologne, Dortmund, Dresden, Düsseldorf, Essen
2022-03-02
Active, closed
Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)
NCT05051033Mitral Valve Regurgitation
Annetine Gelijns
Not applicable
450
Cologne, Bad Oeynhausen, Bad Nauheim, Bad Rothenfelde, Berlin, Frankfurt, Freiburg im Breisgau, Hamburg
2022-02-21
Active, closed
Setrusumab vs Placebo for Osteogenesis Imperfecta
NCT05125809Osteogenesis Imperfecta
DrugSetrusumab
Ultragenyx Pharmaceutical Inc
Phase 2/3
183
Cologne, Magdeburg, Würzburg
2022-02-21
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
DrugsDomvanalimab·Durvalumab
AstraZeneca
Phase 3
791
Berlin, Berlin-Zehlendorf, Braunschweig, Chemnitz, Cologne, Erlangen, Essen, Giessen
2022-02-18
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
DrugAnifrolumab
AstraZeneca
Phase 3
363
Cologne, Dresden, Hanover, Heidelberg, Kirchheim, Mainz Am Rhein
2022-02-15
Recruiting
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
NCT04879043Multiple Myeloma, Plasma Cell Disorder
DrugHDP-101
Heidelberg Pharma AG
Phase 1/2
78
Berlin, Chemnitz, Cologne, Hamburg, Heidelberg, Kiel, Lübeck, Mainz
2022-02-07
Active, closed
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049Crohn Disease
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3
Janssen Research & Development, LLC
Phase 3
350
Berlin, Braunschweig, Cologne, Dachau, Duisburg, Halle, Hanover, Jerichow
2022-01-19
Active, closed
A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
NCT05470595Large Cell Neuroendocrine Carcinoma of the Lung
DrugAtezolizumab
Technische Universität Dresden
Phase 2
67
Berlin, Cologne, Dresden, Frankfurt am Main, Gauting, Großhansdorf, Halle, Heidelberg
2022-01-18
Recruiting
The "Global Paradise System" Registry
NCT05027685Hypertension
ReCor Medical, Inc.
Observational
3,000
Ahrweiler, Bad Krozingen, Berlin, Coburg, Cologne, Detmold, Dresden, Düsseldorf
2022-01-13
Recruiting
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
NCT05118789Locally Advanced Solid Tumor, Metastatic Solid Tumor
Nuvalent Inc.
Phase 1/2
359
Cologne
2022-01-04
Active, closed
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
NCT05038735Breast Cancer
DrugsAlpelisib·Fulvestrant
Novartis Pharmaceuticals
Phase 3
210
Cologne, Augsburg, Berlin, Essen, Lübeck
2021-12-17
Active, closed
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
NCT05182385ALL, Recurrent, Adult
DrugsVenclyxto·Blinatumomab·Venetoclax
Goethe University
Phase 1/2
30
Tübingen, Ulm, Frankfurt am Main, Dresden, Berlin, Cologne, Düsseldorf, Erlangen
2021-12-15
Active, closed
From the Emergency Department Directly to Ablation of Atrial Fibrillation Study
NCT05294445Atrial Fibrillation (AF)
Asklepios proresearch
Not applicable
350
Bad Nauheim, Berlin, Cologne, Düsseldorf, Frankfurt, Giessen, Hamburg, Hamburg-Nord
2021-12-15
Active, closed
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
NCT04982393Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals
Observational
207
Berlin, Cologne, Hamburg
2021-12-13
Active, closed
Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer
NCT04246203Pancreas Cancer
Ludwig-Maximilians - University of Munich
Observational
200
Munich, Berlin, Cologne, Hamburg, Ulm
2021-12-12
Active, closed
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016Relapsed/Refractory Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 2
222
Cologne, Großhansdorf, Würzburg
2021-12-01
Recruiting
HIV Resistance, Molecular Epidemiology and New Treatment Strategies in the Eastern European Region and in Russia
NCT06127290HIV-1-infection
Euresist Network GEIE
Observational
200
Cologne
2021-12-01
Recruiting
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05160584Relapsed/Refractory Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium
Observational
300
Berin, Cologne, Dresden, Hamburg, Hamm, Heidelberg, Karlsruhe, Leipzig
2021-11-18
Recruiting
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
NCT05281406NSCLC Stage IIIB, NSCLC Stage IV
DrugsTagrisso·Osimertinib·Pemetrexed·Cisplatin
Goethe University
Phase 2
50
Berlin, Cologne, Dresden, Essen, Frankfurt, Gauting, Georgsmarienhütte, Göttingen
2021-11-12
Active, closed
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 3
454
Cologne, Dresden, Mainz, München, Oldenburg
2021-10-28
Active, closed
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT04861259Atypical Hemolytic Uremic Syndrome
DrugCrovalimab
Hoffmann-La Roche
Phase 3
83
Cologne, Essen, Hanover
2021-10-22
Active, closed
Low-dose Atropine for Myopia Control in Children
NCT03865160Myopia, Progressive
DrugAtropine eye
University Eye Hospital, Freiburg
Phase 2/3
302
Ahaus, Bonn, Cologne, Erlangen, Essen, Freiburg im Breisgau, Göttingen, Hamburg
2021-10-19
Active, closed
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696Systemic Lupus Erythematosus
Beeline Medicines Corporation
Phase 2
248
Cologne, Berlin, Essen, Freiburg im Breisgau
2021-10-11
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
645
Cologne, Dresden, Leipzig, Lübeck, Mainz, München, Ulm
2021-09-13
Active, closed
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
NCT04765059Non-small Cell Lung Cancer
DrugCarboplatin
AstraZeneca
Phase 3
98
Berlin, Cologne, Hanover, München
2021-09-12
Active, closed
RanDOmized stUdy Comparing Both Latest Generation Self-Expanding Valves and a Minimalist approaCH vs. Standard Of Care In transCathEter Aortic Valve Implantation
NCT05036018Aortic Valve Stenosis
Leipzig Heart Science gGmbH
Not applicable
836
Bad Berka, Bad Oeynhausen, Cologne, Dortmund, Giessen, Leipzig, München, Tübingen
2021-08-30
Active, closed
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
NCT05049798Arthritis, Psoriatic
DrugsIL-17i·Tremfya·Guselkumab
Janssen Pharmaceutica N.V., Belgium
Observational
1,314
Amberg, Bayreuth, Berlin, Cologne, Düsseldorf, Erfurt, Frankfurt, Halle
2021-08-25
Recruiting
A Registry Study on HIV-related Lymphoma
NCT05231135AIDS Related Lymphoma, HIV Related Lymphoma
Rotkreuzklinikum München gGmbH
Observational
300
Munich, Cologne
2021-08-25
Active, closed
STOP Persistent AF PAS
NCT05005949Persistent Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
400
Cologne, Frankfurt am Main, München
2021-08-19
Recruiting
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
NCT04844866Diffuse Large B-cell Lymphoma
Miltenyi Biomedicine GmbH
Phase 2
213
Augsburg, Bochum, Cologne, Erlangen, Essen, Hamburg, Heidelberg, Leipzig
2021-08-18
Recruiting
Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy
NCT04629833Steroid-refractory Acute Graft-versus-host Disease
DrugMC0518
medac GmbH
Phase 3
210
Munich, Würzburg, Frankfurt am Main, Hanover, Cologne, Essen, Münster, Dresden
2021-08-16
By invitation
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
NCT04957719Acute Myocardial Infarction
Viatris Innovation GmbH
Phase 3
25,000
Bad Krozingen, Bad Oeynhausen, Berlin, Bonn, Cologne, Dortmund, Dresden, Hamburg
2021-08-14
Recruiting
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
DrugSparsentan
Travere Therapeutics, Inc.
Phase 2
67
Cologne, Hamburg, Heidelberg
2021-08-12
Active, closed
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
DrugsChidamide·Nivolumab
HUYABIO International, LLC.
Phase 3
450
Berlin, Cologne, Dresden, Erfurt, Essen, Freiburg im Breisgau, Heidelberg, Leipzig
2021-08-12
Recruiting
European Disease Registry on Retinopathy of Prematurity (ROP)
NCT04939571Retinopathy of Prematurity
University Medicine Greifswald
Observational
3,000
Aachen, Berlin, Bonn, Braunschweig, Chemnitz, Cologne, Cottbus, Düsseldorf
2021-08-06
Active, closed
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709Muscle Invasive Bladder Cancer
DrugsEnfortumab Vedotin·Tremelimumab·Durvalumab
AstraZeneca
Phase 3
712
Bielefeld, Bochum, Cologne, Düsseldorf, Giessen, Hanover, Herne, Magdeburg
2021-08-05
Active, closed
Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer
NCT04733118Early Breast Cancer
MedSIR
Phase 2
393
Cologne, Duisburg, Essen, Manheim, Potsdam
2021-08-05
Active, closed
Pulmonary Embolism International THrOmbolysis Study-3
NCT04430569Pulmonary Embolism
DrugAlteplase
Assistance Publique - Hôpitaux de Paris
Phase 3
800
Bad Krozingen, Berlin, Cologne, Dresden, Düsseldorf, Freiburg im Breisgau, Greifswald, Hanover
2021-08-04
Recruiting
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618C3G
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
98
Cologne, Aachen, Erlangen, Essen, Hamburg, Hanover, Heidelberg, Mainz
2021-07-28
By invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
760
Cologne, Freiburg im Breisgau, Herne, Leipzig, Tübingen, Vogelsang-gommern
2021-07-27
Recruiting
German Cardiac Arrest Registry
NCT05142124Out-of-hospital Cardiac Arrest
Leipzig Heart Science gGmbH
Observational
400
Berlin, Bad Friedrichshall, Bonn, Bremen, Cologne, Dresden, Düsseldorf, Essen
2021-07-21
Recruiting
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
NCT04877288Renal Allograft Recipients
DrugsCyclosporine A·Belatacept·Mycophenolate Mofetil·Tacrolimus
Bristol-Myers Squibb
Phase 3
102
Essen, Cologne, Hamburg, Heidelberg
2021-07-21
Active, closed
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567Lupus Erythematosus, Systemic
DrugLitifilimab
Biogen
Phase 3
562
Göttingen, Hanover, Cologne, Münster, Mainz
2021-07-16
Active, closed
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
NCT04908189Psoriatic Arthritis
DrugsApremilast·Deucravacitinib
Bristol-Myers Squibb
Phase 3
729
Ratingen, Cologne, Erlangen, Hamburg, Magdeburg, Minden, Tübingen
2021-07-15
Active, closed
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
NCT04657289Neovascular Age-related Macular Degeneration (nAMD)
DrugRanibizumab
Hoffmann-La Roche
Phase 3
451
Bonn, Cologne, Cottbus, Freiburg im Breisgau, Hamburg, Ludwigshafen, München, Münster
2021-07-14
Recruiting
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
NCT04803994Hepatocellular Carcinoma
DrugsTecentriq·Avastin·Atezolizumab·Bevacizumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3
434
Aachen, Amberg, Berlin, Bochum, Cologne, Dresden, Düsseldorf, Erlangen
2021-07-06
Active, closed
Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease
NCT05043103Advanced Parkinson Disease
Britannia Pharmaceuticals Ltd.
Observational
312
Bad Segeberg, Beelitz-Heilstätten, Berlin, Cologne, Coppenbrügge, Essen, Freiburg im Breisgau, Göttingen
2021-07-06
Active, closed
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer
DrugZongertinib
Boehringer Ingelheim
Phase 1
554
Augsburg, Cologne, Dresden, Giessen, Oldenburg
2021-07-02
Active, closed
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755Neoplasms, Breast
DrugNiraparib
GlaxoSmithKline
Phase 3
40
Berlin, Cologne, Erlangen, Essen, Mannheim, München, Ulm
2021-06-28
Recruiting
Device Global Registry for the IlluminOss Bone Stabilization System
NCT05206981Traumatic Fracture, Pathological Fracture
IlluminOss Medical, Inc.
Observational
300
Cologne, Minden, Wuppertal
2021-06-11
Active, closed
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157Prostatic Neoplasms
DrugsARDT·Illuccix·Lu-PSMA
Novartis Pharmaceuticals
Phase 3
1,140
Würzburg, Cologne, Essen, München, Münster, Rostock
2021-06-09
Active, closed
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
NCT04877691Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
367
Berlin, Cologne, Leipzig, Tübingen
2021-06-08
Active, closed
Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse
NCT04656951Multiple Myeloma
DrugsDarzalex·Daratumumab
University of Cologne
Phase 2
67
Cologne
2021-06-01
Active, closed
The SELUTION DeNovo Study
NCT04859985Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
3,326
Augsburg, Bad Krozingen, Berlin, Bremen, Bruchsal, Cologne, Dresden, Essen
2021-05-15
Recruiting
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
NCT07218029Pulmonary Arterial Hypertension
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 3
815
Heidelberg, Munich, Regensburg, Giessen, Hanover, Cologne, Dresden, Leipzig
2021-05-12
Active, closed
Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation
NCT04818502Mitral Valve Regurgitation
Abbott Medical Devices
Observational
200
Bad Oeynhausen, Berlin, Bonn, Cologne, Frankfurt, Hamburg, Kiel, Leipzig
2021-05-04
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
DrugPhase 2
enGene, Inc.
Phase 1/2
350
Cologne, Duisburg, Erlangen, Mettmann, Nürtingen, Tübingen
2021-04-22
Recruiting
Tendyne European Experience Registry
NCT04898335Mitral Regurgitation
LMU Klinikum
Observational
400
Bad Oeynhausen, Berlin, Bonn, Cologne, Frankfurt, Hamburg, Leipzig, Mainz
2021-04-15
Active, closed
TRISCEND II Pivotal Trial
NCT04482062Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases
Edwards Lifesciences
Not applicable
864
Bad Oeynhausen, Bonn, Cologne, Dresden, Leipzig, Mainz, München
2021-04-09
Recruiting
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
NCT04655404High Grade Glioma, Diffuse Intrinsic Pontine Glioma
DrugLarotrectinib
Nationwide Children's Hospital
Phase EARLY_PHASE1
15
Heidelberg, Augsburg, Berlin, Cologne, Göttingen
2021-04-08
Recruiting
A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).
NCT05331521Oligodendroglioma
DrugProcarbazine
University Hospital Heidelberg
Phase 3
406
Heidelberg, Berlin, Bochum, Bonn, Chemnitz, Cologne, Düsseldorf, Frankfurt
2021-04-07
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Ulm, Cologne, Siegen, Dresden
2021-04-05
Active, closed
Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP
NCT04985318Acquired Thrombotic Thrombocytopenic Purpura
University of Cologne
Observational
350
Cologne
2021-03-25
Active, closed
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318Chronic Lymphoid Leukemia
DrugsVenclyxto·Ibrutinib·Obinutuzumab·Venetoclax
German CLL Study Group
Phase 3
897
Augsburg, Berlin, Bremen, Cologne, Dortmund, Dresden, Düsseldorf, Eisenach
2021-03-01
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Freiburg im Breisgau, Cologne, Dresden, Essen
2021-02-24
Active, closed
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
DrugsAdagrasib·Taxotere·Docetaxel
Mirati Therapeutics Inc.
Phase 3
453
Bad Berka, Bonn, Cologne, Essen, Gauting, Giessen, Grohansdorf, Halle
2021-02-23
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Köln, Cologne, Großhansdorf, Dresden
2021-02-02
Recruiting
CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1
NCT04455282Cancer of Esophagus, Esophagogastric Junction Disorder
Heinrich-Heine University, Duesseldorf
Observational
100
Cologne, Münster
2021-02-01
Active, closed
Transcatheter Repair of Tricuspid Regurgitation With Edwards PASCAL Transcatheter Valve Repair System
NCT04614402Tricuspid Valve Insufficiency
Edwards Lifesciences
Observational
300
Tübingen, Ulm, München, Cologne, Essen, Bad Oeynhausen, Bonn, Leipzig
2021-01-15
Active, closed
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT04628494Diffuse Large B-cell Lymphoma
DrugEpcoritamab
Genmab
Phase 3
483
Cologne, Essen, Kiel, Würzburg
2021-01-13
Active, closed
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
DrugPembrolizumab
BioNTech SE
Phase 2/3
358
Berlin, Cologne, Hanover, Heidelberg, Iserlohn, Leipzig, Mainz, München
2021-01-07
Active, closed
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
NCT04521231B Cell Precursor Acute Lymphoblastic Leukemia
DrugBlinatumomab
Amgen
Phase 1/2
181
Augsburg, Berlin, Cologne, Jena, Leipzig, Tübingen, Ulm
2021-01-04
Active, closed
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652Non-small Cell Lung Cancer
DrugsDato-DXd·Docetaxel
Daiichi Sankyo
Phase 3
605
Berlin, Cologne, Frankfurt am Main, Freiburg im Breisgau, Gauting, Heidelberg, Hemer, Kempten
2020-12-21
Active, closed
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623Urinary Bladder Neoplasms
DrugsTAR-200·Cetrelimab
Janssen Research & Development, LLC
Phase 2
220
Cologne, Duisburg, Herne, Markkleeberg, Mettmann, Münster, Nuremberg, Nürtingen
2020-12-18
Active, closed
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555Non-Small Cell Lung Cancer
DrugsTagrisso·Osimertinib·Pemetrexed·Cisplatin
AstraZeneca
Phase 3
358
Berlin, Bielefeld, Cologne, Esslingen a.N., Freiburg im Breisgau, Gauting, Georgsmarienhütte, Halle
2020-12-16
Active, closed
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
NCT04522544Hepatocellular Carcinoma Non-resectable, HCC
DrugsTremelimumab·Durvalumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
55
Bonn, Cologne, Essen, Göttingen, Hanover, Jena, Lübeck, München
2020-12-15
Active, closed
Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
NCT04295447Prostatic Neoplasms
DrugApalutamide Tab
Universität Münster
Phase 2
190
Münster, Augsburg, Bergisch Gladbach, Cologne, Duisburg, Düsseldorf, Essen, Frankfurt
2020-12-10
Active, closed
AMEND-CRT: Mechanical Dyssynchrony as Selection Criterion for CRT
NCT04225520Left Ventricular Dyssynchrony, Heart Failure, Cardiomyopathy, Dilated, Cardiac Remodeling, Ventricular
Universitaire Ziekenhuizen KU Leuven
Not applicable
500
Cologne, Rostock, Würzburg
2020-12-10
Active, closed
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
NCT04655976Lung Cancer, Non-Small Cell
DrugsCobolimab·Dostarlimab·Docetaxel
GlaxoSmithKline
Phase 2/3
758
Augsburg, Bad Berka, Berlin, Bonn, Cologne, Dresden, Essen, Frankfurt
2020-12-08
Active, closed
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
DrugsTrastuzumab emtansine·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 3
1,600
Augsburg, Berlin, Bielefeld, Böblingen, Braunschweig, Bremen, Chemnitz, Cologne
2020-12-04
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsAdagrasib·Pembrolizumab
Mirati Therapeutics Inc.
Phase 2/3
626
Immenstadt im Allgäu, Amberg, Augsburg, Bad Homburg, Berlin, Braunschweig, Chemnitz, Cologne
2020-12-02
Active, closed
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
DrugsEpcoritamab·Pirtobrutinib·Lenalidomide·Venetoclax
Genmab
Phase 1/2
194
Cologne, Kiel
2020-11-25
Recruiting
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
NCT04111978Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC)
DrugLetrozole
Swiss GO Trial Group
Phase 3
540
Berlin, Cologne, Deggendorf, Dresden, Düsseldorf, Essen, Esslingen am Neckar, Freiburg im Breisgau
2020-11-05
Recruiting
CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry
NCT04688190Mitral Regurgitation, Mitral Valve Disease, Mitral Annular Calcification
Universitätsklinikum Hamburg-Eppendorf
Observational
1,000
Bad Oeynhausen, Berlin, Bonn, Cologne, Frankfurt, Hamburg, Lübeck, Mainz
2020-11-01
Recruiting
The AFteR Registry - Follow-up Study to Monitor the Efficacy and Safety of the Occlutech AFR in Heart Failure Patients
NCT04405583Heart Failure
Occlutech International AB
Observational
150
Bottrop, Coburg, Cologne, Erfurt, Hamburg, Heide, Jena, Osnabrück
2020-10-28
Active, closed
IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact
NCT04221815Atherosclerosis
Medstar Health Research Institute
Not applicable
3,100
Bad Oeynhausen, Cologne, Bad Segeberg, Dachau, Hamburg, Neuss, Rostock
2020-10-14
Active, closed
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664Carcinoma, Non-Small-Cell Lung
DrugsAmivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
308
Bad Berka, Berlin, Cologne, Gauting, Heidelberg, Heilbronn, Moers, Oldenburg
2020-10-13
Active, closed
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
NCT04515238Chronic Lymphoid Leukemia
DrugsVenclyxto·Bendamustine·Zanubrutinib·Obinutuzumab
German CLL Study Group
Phase 2
42
Augsburg, Cologne, Esslingen am Neckar, Hamm, Homburg, Kiel, Mönchengladbach, Munich
2020-10-01
Recruiting
Characterization of Antibacterial Antibodies in Patients With Cystic Fibrosis
NCT04700358Pulmonary Cystic Fibrosis, Neutralizing Antibodies
University Hospital of Cologne
Observational
75
Cologne
2020-10-01
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Osimertinib
Janssen Research & Development, LLC
Phase 3
1,074
Bad Berka, Berlin, Cologne, Essen, Gauting, Halle, Heidelberg, Heilbronn
2020-09-30
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844Prostatic Neoplasms
DrugsAbiraterone acetate·Prednisone
Janssen Research & Development, LLC
Phase 3
696
Braunschweig, Cologne, Dresden, Duisburg, Hanover, München, Münster, Nürtingen
2020-09-23
Active, closed
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
NCT04280718Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
DrugEfgartigimod PH20
argenx
Phase 2
229
Bochum, Cologne, Essen, Göttingen, Kiel, Potsdam
2020-09-18
Active, closed
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
NCT04503278Solid Tumor
BioNTech Cell & Gene Therapies GmbH
Phase 1
214
Berlin, Cologne, Erlangen, Hamburg, Hanover, Heidelberg, Mainz, Regensburg
2020-09-16
Active, closed
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)
NCT01817192Non-Small Cell Lung Cancer
Razor Genomics
Not applicable
420
Cologne, Gauting, Georgsmarienhütte, Großhansdorf, Hanover, Lübeck, München, Oldenburg
2020-09-11
Active, closed
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748Myelodysplastic Syndrome (MDS)
DrugsVenclexta·Azacitidine·Venetoclax
AbbVie
Phase 3
531
Mannheim, Mutlangen, Munich, Hanover, Cologne, Düsseldorf, Leipzig, Berlin
2020-09-10
Active, closed
MINIject Global Long-Term Follow-up Study
NCT04524416Open Angle Glaucoma, Ocular Hypertension
iSTAR Medical
Observational
116
Cologne, Mainz, München
2020-08-05
Active, closed
A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
NCT04429087Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
DrugObrixtamig
Boehringer Ingelheim
Phase 1
306
Cologne, Dresden, Würzburg
2020-07-29
Active, closed
STABILITY 2: Anterior Cruciate Ligament Reconstruction +/- Lateral Tenodesis With Patellar vs Quad Tendon
NCT03935750Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Reconstruction, Joint Instability
University of Pittsburgh
Not applicable
1,272
Cologne, Münster
2020-07-28
Active, closed
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
NCT04245839Lymphoma, Non-Hodgkin
DrugsBreyanzi·Fludarabine·Cyclophosphamide
Celgene
Phase 2
276
Ulm, Regensburg, Cologne, Karlsruhe, Munich
2020-07-14
Active, closed
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04181827Multiple Myeloma
DrugsCilta-cel·Pomalidomide·Bortezomib·Daratumumab
Janssen Research & Development, LLC
Phase 3
419
Cologne, Dresden, Hamburg, Leipzig, Tübingen, Würzburg
2020-06-12
Active, closed
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
NCT04106219Neuroblastoma
DrugsTopotecan·Cyclophosphamide
Eli Lilly and Company
Phase 1
71
Cologne
2020-06-11
Recruiting
International CIPN Assessment and Validation Study
NCT04633655Chemotherapy-induced Peripheral Neuropathy, Quality of Life
University of Milano Bicocca
Observational
1,000
Cologne
2020-06-08
Active, closed
Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients With Bone Metastases
NCT04307914Bone Metastases, Bone Neoplasm, Bone Lesion, Bone Cancer
UMC Utrecht
Not applicable
216
Cologne
2020-03-10
Recruiting
Leptospirosis Registry - LeptoScope
NCT04288674Leptospirosis
University of Cologne
Observational
200
Cologne
2020-03-04
Recruiting
Hantavirus Registry - HantaReg
NCT04323904Hantavirus Infections, Hemorrhagic Fever With Renal Syndrome, Nephropathia Epidemica, Hantavirus Cardiopulmonary Syndrome
University of Cologne
Observational
200
Cologne
2020-03-04
Rows per page Showing 1–500 of 612
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 1 October 2026. https://priyalifescience.com/clinical-trials-germany/city/cologne

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 612 of those studies with a site in Cologne.

How many clinical trials are recruiting in Cologne?

312 of the 612 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 27 have not yet opened recruitment, 261 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cologne), 612 studies
PhaseStudiesRecruitingShare
Phase 324210439.5%
Observational1218219.8%
Phase 2864214.1%
Not applicable703411.4%
Phase 1/241276.7%
Phase 128114.6%
Phase 2/31792.8%
Phase 4621%
Phase EARLY_PHASE1110.2%

Most active sponsors

Lead sponsors with the most studies (Cologne)
Lead sponsorStudiesRecruiting
AstraZeneca4822
Novartis Pharmaceuticals2910
University of Cologne2517
Bristol-Myers Squibb2110
Janssen Research & Development, LLC216
Eli Lilly and Company209
Boehringer Ingelheim1510
AbbVie146
Hoffmann-La Roche145
Amgen123
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.